<SEC-DOCUMENT>0001193125-22-180042.txt : 20220623
<SEC-HEADER>0001193125-22-180042.hdr.sgml : 20220623
<ACCEPTANCE-DATETIME>20220623160257
ACCESSION NUMBER:		0001193125-22-180042
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20220623
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Submission of Matters to a Vote of Security Holders
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220623
DATE AS OF CHANGE:		20220623

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TEVA PHARMACEUTICAL INDUSTRIES LTD
		CENTRAL INDEX KEY:			0000818686
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-16174
		FILM NUMBER:		221035427

	BUSINESS ADDRESS:	
		STREET 1:		5 BAZEL ST
		STREET 2:		P O B 3190
		CITY:			PETACH TIKVA
		STATE:			L3
		ZIP:			49131
		BUSINESS PHONE:		9729267267

	MAIL ADDRESS:	
		STREET 1:		TEVA PHARMACEUTICAL INDUSTRIES LIMITED
		STREET 2:		5 BAZEL ST PO B 3190
		CITY:			PETACH TIKVA
		STATE:			L3
		ZIP:			49131
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d730888d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:teva="http://www.tevapharm.com/20220623" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityRegistrantName" name="dei:EntityRegistrantName" contextRef="duration_2022-06-23_to_2022-06-23">TEVA PHARMACEUTICAL INDUSTRIES LTD</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityAddressCountry" name="dei:EntityAddressCountry" contextRef="duration_2022-06-23_to_2022-06-23">IL</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityTaxIdentificationNumber" name="dei:EntityTaxIdentificationNumber" contextRef="duration_2022-06-23_to_2022-06-23">00-0000000</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2022-06-23_to_2022-06-23">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2022-06-23_to_2022-06-23">0000818686</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_CurrentFiscalYearEndDate_duration_2022-06-23_to_2022-06-23" name="dei:CurrentFiscalYearEndDate" contextRef="duration_2022-06-23_to_2022-06-23">--12-31</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="teva-20220623.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2022-06-23_to_2022-06-23"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-06-23</xbrli:startDate> <xbrli:endDate>2022-06-23</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2022-06-23_to_2022-06-23">8-K</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Current Report</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported) <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2022-06-23_to_2022-06-23" format="ixt:datemonthdayyearen">June 23, 2022</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <span style=" -sec-ix-hidden:Hidden_dei_EntityRegistrantName">TEVA PHARMACEUTICAL INDUSTRIES LIMITED</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrants as specified in its charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2022-06-23_to_2022-06-23" format="ixt-sec:edgarprovcountryen">Israel</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2022-06-23_to_2022-06-23">001-16174</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"> <span style=" -sec-ix-hidden:Hidden_dei_EntityTaxIdentificationNumber">Not Applicable</span> </span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(State or other jurisdiction<br />of Incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Commission<br />File Number)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(IRS Employer<br />Identification Number)</span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2022-06-23_to_2022-06-23">124 Dvora Hanevi&#8217;a Street</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2022-06-23_to_2022-06-23">Tel Aviv</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2022-06-23_to_2022-06-23">6944020</ix:nonNumeric>, <span style=" -sec-ix-hidden:Hidden_dei_EntityAddressCountry">Israel</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of Principal Executive Offices, including Zip Code)</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">+<ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2022-06-23_to_2022-06-23">972</ix:nonNumeric>-<ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2022-06-23_to_2022-06-23">3-914-8213</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s Telephone Number, including Area Code)</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2022-06-23_to_2022-06-23" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2022-06-23_to_2022-06-23" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2022-06-23_to_2022-06-23" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2022-06-23_to_2022-06-23" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section 12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br />Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br />on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2022-06-23_to_2022-06-23">American Depositary Shares,<br />each representing one Ordinary Share</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2022-06-23_to_2022-06-23">TEVA</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2022-06-23_to_2022-06-23" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">Emerging Growth Company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2022-06-23_to_2022-06-23" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. &#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;5.03</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva Pharmaceutical Industries Limited (&#8220;Teva&#8221; or the &#8220;Company&#8221;) held its Annual Meeting on June 23, 2022 (the &#8220;Annual Meeting&#8221;). At the Annual Meeting, Teva&#8217;s shareholders approved an amendment to the Company&#8217;s Articles of Association (the &#8220;Articles&#8221;), effective upon approval on June&#160;23, 2022, to, among other things, (i)&#160;eliminate the requirement for a minimum number of <span style="white-space:nowrap">in-person</span> meetings of the Company&#8217;s Board of Directors (the &#8220;Board&#8221;), (ii) provide the Chairman of the Company&#8217;s Board with discretion to determine, with respect to each year, whether a majority of the <span style="white-space:nowrap">in-person</span> meetings of the Board shall be convened in Israel, (iii)&#160;provide that the CEO shall lead the management team and manage the Company from its headquarters in Israel, (iv)&#160;stipulate that the English language version of the Articles shall be the binding version, (v)&#160;clarify that the Board shall set the maximum number of directors to be appointed at each general meeting, (vi)&#160;amend or remove certain additional provisions that either are obsolete or no longer desirable due to changes in Teva&#8217;s governance structure or amendments to the Israeli Companies Law, 5759-1999, (vii) address Teva&#8217;s unique status as a company subject to both applicable Israeli and U.S. laws, rules and regulations and (viii)&#160;correct minor ambiguities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing description is qualified in its entirety by reference to the full text of the amended Articles of Association which is attached hereto as Exhibit 3.1 </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;5.07</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Submission of Matters to a Vote of Security Holders. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described above, Teva held its Annual Meeting on June 23, 2022. The following is a summary of the matters voted on at the meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1)&#160;&#160;&#160;&#160;The shareholders elected to appoint the following persons to the Board, each to serve until Teva&#8217;s 2025 annual meeting of shareholders, as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:56%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Directors</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">For</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Against</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Abstain</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold"><span style="white-space:nowrap">Brokers&#160;non-vote</span></span></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amir Elstein</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">444,521,760</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">139,011,657</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">602,002</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">110,547,422</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Roberto A. Mignone</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">469,539,322</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">113,977,054</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">619,040</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">110,547,425</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dr.&#160;Perry&#160;D. Nisen</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">473,460,959</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">110,070,839</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">603,618</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">110,547,425</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dr.&#160;Tal Zaks</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">475,714,380</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">107,826,034</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">595,006</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">110,547,421</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2)&#160;&#160;&#160;&#160;The shareholders approved, on a <span style="white-space:nowrap">non-binding</span> advisory basis, the compensation for Teva&#8217;s named executive officers listed in the proxy statement for the Annual Meeting, as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:26%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:23%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:23%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:22%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">For</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Against</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Abstain</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="white-space:nowrap">Brokers&#160;non-vote</span></p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom" align="center">424,554,002</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">137,783,772</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">21,797,642</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">110,547,425</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3)&#160;&#160;&#160;&#160;The shareholders approved Teva&#8217;s Compensation Policy with respect to the terms of office and employment of Teva&#8217;s Executive Officers and Directors as follows. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:54%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">For</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Against</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Abstain</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold"><span style="white-space:nowrap">Brokers&#160;non-vote</span></span></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indicating &#8220;YES&#8221; for personal interest</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">9,100,277</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">2,142,511</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">120,718</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">0</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indicating &#8220;NO&#8221; for personal interest</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">415,051,270</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">126,286,322</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">21,564,100</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">0</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">424,151,547</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">128,428,833</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">21,684,818</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">0</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(4)&#160;&#160;&#160;&#160;The shareholders approved amendments to Teva&#8217;s Articles, as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:26%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:23%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:23%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:22%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">For</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Against</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Abstain</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="white-space:nowrap">Brokers&#160;non-vote</span></p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom" align="center">523,934,723</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">58,788,742</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">1,411,956</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">110,547,420</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(5)&#160;&#160;&#160;&#160;The shareholders approved the appointment of Kesselman&#160;&amp; Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva&#8217;s independent registered public accounting firm until Teva&#8217;s 2023 annual meeting of shareholders, as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:26%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:23%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:23%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:22%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">For</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Against</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Abstain</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="white-space:nowrap">Brokers&#160;non-vote</span></p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom" align="center">667,890,796</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">21,659,403</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">1,296,846</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">0</td></tr>
</table> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:7%"></td>
<td style="width:90%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Exhibit&#160;No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description of Document</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">3.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d730888dex31.htm">Articles of Association </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:47%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:5%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:46%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="3" style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">TEVA PHARMACEUTICAL INDUSTRIES LIMITED</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Date: June&#160;23, 2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Eli Kalif</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Name:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Eli Kalif</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title: </p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Executive Vice President, Chief Financial Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>d730888dex31.htm
<DESCRIPTION>EX-3.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLES OF ASSOCIATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>of </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TEVA PHARMACEUTICAL
INDUSTRIES LIMITED </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A Limited Liability Company </P>
<P STYLE="margin-top:600pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Updated on June&nbsp;23, 2022 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U><A NAME="toc1"></A>TABLE OF CONTENTS </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#appb730888_1"><B>A. INTRODUCTION</B></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#appb730888_2"><B>Interpretation</B></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#appb730888_3"><B>Objectives and Purpose of the Company</B></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#appb730888_4"><B>Limitation of Liability</B></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#appb730888_5"><B>B. CAPITAL OF THE COMPANY</B></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#appb730888_6"><B>Capital Structure</B></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#appb730888_7"><B>Share Certificates</B></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#appb730888_8"><B>Transfer and Endorsement of Shares</B></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#appb730888_9"><B>Increase and Issue of the Registered Capital</B></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#appb730888_10"><B>Change in the Registered Capital</B></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#appb730888_11"><B>C. GENERAL MEETINGS</B></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#appb730888_12"><B>Deliberations at General Meetings</B></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#appb730888_13"><B>Votes by the Shareholders</B></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#appb730888_14"><B>D. THE BOARD OF DIRECTORS</B></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#appb730888_15"><B>Appointment and Retirement from Office</B></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#appb730888_16"><B>Remuneration of Directors</B></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#appb730888_17"><B>Powers and Duties of the Board of Directors</B></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#appb730888_32">Operations of the Board of Directors </A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#appb730888_18"><B>Committees of the Board of Directors</B></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#appb730888_19"><B>Signature and Minutes</B></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#appb730888_20"><B>E. CEO</B></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#appb730888_21"><B>F. DIVIDEND, RESERVE FUND AND CAPITALIZATION</B></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#appb730888_22"><B>Dividend</B></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#appb730888_23"><B>Reserve Fund</B></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#appb730888_24"><B>Capitalization</B></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#appb730888_25"><B>G. AUDITING AND NOTICES</B></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#appb730888_26"><B>Auditing and Internal Auditor</B></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#appb730888_27"><B>Notices</B></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#appb730888_28"><B>H. EXEMPTION, INSURANCE AND INDEMNIFICATION OF
OFFICERS</B></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#appb730888_29"><B>I. MISCELLANEOUS</B></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#appb730888_30"><B>Amendment of the Articles of Association</B></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#appb730888_31"><B>Special Tender Offer</B></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="appb730888_1"></A><U>A. INTRODUCTION</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="appb730888_2"></A><U>Interpretation</U> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In these Articles of Association (<B>&#147;Articles&#148;</B>), the words which appear in the first column in
the table set forth below shall be interpreted in accordance with the interpretation which is given to them on the same line in the second column thereof. This shall apply as long as the text or context of the matter does not include any statement
which contradicts said meaning or which is not consistent therewith. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Words&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Interpretations</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>the &#147;Company&#148;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Teva Pharmaceutical Industries Ltd.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>the &#147;Companies Law&#148;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">The Israeli Companies Law, 5759-1999, and any other law which shall replace or amend it and which shall apply to the Company and be in force at the time in question and the regulations promulgated thereunder.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#147;Officer&#148;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Office Holder as defined in the Companies Law.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>the &#147;Securities Law&#148;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">The Israeli Securities Law, 5728-1968, or any other law which shall replace or amend it and which shall apply to the Company and be in force at the time in question and the regulations promulgated thereunder.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#147;Authorized Person&#148;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">As defined in Article 47 below.</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The English version of these Articles shall be the sole binding version. Words which are in the singular
form shall be deemed to include the plural form, and vice versa. Words which apply to individual persons shall be deemed to include incorporated entities, unless specified otherwise. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The words and expressions in these Articles not otherwise defined herein shall have the same meaning as that given to them in the Companies
Law, unless they conflict with the content or the subject of that set forth in writing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="appb730888_3"></A><U>Objectives and Purpose of the
Company</U> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The purpose of the Company is to engage in any lawful endeavor. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company&#146;s center of management shall be in Israel, unless the Board of Directors shall otherwise
resolve, with a majority of three quarters of the participating votes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company is entitled to contribute a reasonable amount to a worthy cause, even if the contribution does not
fall within the framework of its business objectives. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="appb730888_4"></A><U>Limitation of Liability</U> </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The liability of the shareholders is limited to the payment of the par value of their shares.
</P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="appb730888_5"></A><U>B. CAPITAL OF THE COMPANY</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="appb730888_6"></A><U>Capital Structure</U> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registered share capital of the Company is NIS 249,434,338 consisting of 2,494,343,376 shares of NIS 0.1
par value each, divided as follows: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">2,494,343,316&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ordinary Shares,
nominal (par) value NIS 0.1&nbsp;per share (&#147;<B>Ordinary Shares</B>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">60
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred Shares, nominal (par) value NIS 0.1 per share (&#147;<B>Deferred Shares</B>&#148;).
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Ordinary Shares shall confer upon the holders thereof equal rights with regard to the receipt of dividends,
the receipt of bonus shares and the distribution of Company property during liquidation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In addition, the Ordinary Shares shall confer upon the holders thereof equal rights with regard to voting and
the right to appoint directors, including pursuant to the provisions of Articles 45 and 56 below. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Deferred Shares shall not confer upon the holders thereof any rights, except for the right to be reimbursed
in the amount of the par value thereof upon liquidation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Should the share capital, at any time whatsoever, be divided into different types of shares, it shall be
permissible to change the rights of any such type (unless otherwise set forth in the terms of issue of the shares of that type) after having obtained the consent, in writing, of all of the shareholders of the shares that have been issued of that
type, or following the adoption of a resolution, by a majority of three-quarters of the participating votes at a meeting of the shareholders of that type. The provisions of these Articles with regard to General Meetings shall also apply, mutatis
mutandis, with regard to such a meeting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company is entitled, subject to the provisions of the Companies Law and these Articles, to issue redeemable
preferred shares or redeemable securities, pursuant to the terms and in the manner which shall be set forth by the Company at a General Meeting, and to redeem said shares or securities. The Company shall be entitled to decide upon the establishment
of a fund or funds for the purpose of redemption of redeemable preferred shares or of other redeemable securities, in whole or in part, and to decide upon the amounts which shall be allocated to said fund or funds and the sources from which said
amounts shall be allocated. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares shall be under the supervision of the Board of Directors, which shall be entitled, subject to the
provisions of the Companies Law and these Articles, to issue them, to grant option rights for the purchase thereof, or to confer them in any manner to such persons, subject to such reservations and at such times as the Board of Directors shall see
fit&#151;provided, however, that no share whatsoever shall be issued at less than its par value, other than pursuant to the provisions of the Companies Law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company is entitled, at any time, to pay a commission to any person who shall underwrite, or shall agree to
underwrite (whether absolutely or conditionally), shares or bonds of the Company, or who shall obtain the commitment of an underwriter, or shall agree to obtain the commitment of an underwriter (whether absolutely or conditionally), with regard to
shares or bonds of the Company. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">However, should the commission with regard to the shares be paid, or be payable, out of
capital, the legal conditions and requirements concerning such payment shall be preserved and upheld. The commission may be paid in cash, in shares or in bonds of the Company, or by way of any two or of all three of said means. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless otherwise stipulated in these Articles, the Company shall be entitled to consider the registered holder
of any share to be the absolute holder of said share, and accordingly, shall not be obligated to recognize any claim in equity or any claim on any other basis which may be filed by any other person with regard to such a share or with regard to any
benefit related to such a share, unless it shall have been instructed to do so by a competent court of law or shall be required to do so by virtue of the provisions of the Companies Law or by virtue of the provisions of any other law.
</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="appb730888_7"></A><U>Share Certificates</U> </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The share certificates shall be issued by the Company and shall bear the properly affixed signature of two
Directors, or of any two of the following: a Director, the Chief Executive Officer <B></B>(&#147;<B>CEO</B>&#148;), the Chief Financial Officer, the Treasurer or the Company Secretary. Each shareholder shall be entitled to receive, free of charge,
one certificate with respect to the shares which are registered in his or her name, or, with the approval of the Board of Directors (against payment of a price which shall be determined by the Board of Directors from time to time), a number of
certificates, each of which shall be issued with respect to one or more of the shares which are held by him or her. The Company shall issue the certificates with respect to fully <FONT STYLE="white-space:nowrap">paid-up</FONT> shares within one
month of the date of the issue thereof, or within one month of the date of receipt of the total consideration with respect thereto, or within one month of the date on which the Company shall have been provided, pursuant to the provisions of the
Companies Law and of these Articles, with the certificate of transfer of the fully <FONT STYLE="white-space:nowrap">paid-up</FONT> shares with respect to which the share certificate is requested. Each share certificate shall designate the numbers of
the shares with respect to which it was issued. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">15.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Should any share certificate become mutilated or defaced, then, following the submission of said certificate to
the Company Secretary, the Board of Directors or the Company Secretary shall be entitled to instruct that said certificate shall be canceled and a new certificate shall be issued in its stead. Should a share certificate become lost or destroyed,
then, following the submission of evidence to the satisfaction of the Board of Directors or the Company Secretary, and following the submission of such guarantee of indemnification and compensation for damages as the Board of Directors or the
Company Secretary shall see fit to require, another certificate shall be delivered in its stead to the person who is entitled to the certificate which became lost or destroyed, against such payment as shall be determined by the Board of Directors or
the Company Secretary from time to time. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">16.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A share certificate which is registered in the names of two or more persons shall be delivered to that person
whose name is listed first in the Register or in an Additional Register. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="appb730888_8"></A><U>Transfer and Endorsement of
Shares</U> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">17.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall maintain registers according to the Companies Law (&#147;<B>Register</B>&#148;), and in
addition, it is entitled to maintain additional registers of shareholders outside Israel (&#147;<B>Additional Register</B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">18.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No transfer of any share shall be registered unless a certificate of transfer shall have been submitted to the
Company, in the usual form or in a form which shall be set forth by the Board of Directors or the Company Secretary from time to time. A certificate of transfer of any share shall be signed by the transferor and the transferee, or by persons on
their behalf. The Board of Directors or the Company Secretary, at their sole discretion, is entitled to decide that, in cases of transfer of fully <FONT STYLE="white-space:nowrap">paid-up</FONT> shares, the certificate of transfer shall be signed by
or on behalf of the transferor alone. In addition, the Board of Directors or the Company Secretary, at their sole discretion, are entitled to decide that there shall be no need for the signature of a witness in order to validate the signatures which
appear on the certificate of transfer. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The transferor shall be deemed to be the holder of a transferred share until the
name of the transferee shall have been registered in the Register with regard to said share. With regard to shares which are registered in an Additional Register, a certificate of transfer may be drawn up in the form, and may be signed in the
manner, which shall be permitted or customary, according to the Companies Law or prevailing procedure, in the country in which the Additional Register is maintained. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">19.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each certificate of transfer shall be handed in for registration at the Registered Office, or the office where
an Additional Register of the Company is maintained (whichever is relevant), or in </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
any other place, as the Board of Directors or the Company Secretary shall set forth from time to time. The share certificates with respect to the transferred shares, and any other evidence which
the Board of Directors or the Company Secretary shall require, in order to prove the transferor&#146;s right of ownership or his or her right to transfer the shares, shall be attached to said certificate of transfer. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">20.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board of Directors is entitled to refuse to register or to confirm the transfer of shares, until the shares
whose transfer is desired or any part thereof shall have been fully paid up. The fact of whether or not the refusal applies to a transferee who is the holder of a share in the Company shall have no relevance. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">21.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The executors of the will or of the estate of an individual shareholder who has died&#151;or, in cases where
there are no executors of a will or of the estate, the persons who have been declared by a competent court of law to hold a right of benefit, in the capacity of the heirs of said individual shareholder who has died&#151;shall be the only persons who
shall be recognized by the Company as the holders of a right in any share which is registered in the name of the deceased individual. Should a share be registered in the names of two or more shareholders, the Company shall recognize only the
surviving partner or the surviving partners, or the executors of the will or of the estate of the last partner to have died, as the holders of a right in said share, and, should there be no executor of a will or of the estate (of the last deceased
partner), the Company shall recognize, as the holders of a right in said share, only the persons who have been declared by a competent court of law to hold a right of benefit, in the capacity of the heirs of the last deceased partner.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">22.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any person or entity that has become entitled to a share as the result of the death or bankruptcy of a
shareholder shall be entitled&#151;after having provided such evidence as the Board of Directors or the Company Secretary shall require of that person or entity from time to time&#151;to be registered as a shareholder with respect to said share, or,
instead of being personally registered as a shareholder, to perform any transfer which the deceased or bankrupt shareholder could have performed. However, in any such case, the Board of Directors shall be entitled to refuse or to delay registration,
as it would have been entitled to do in the case of transfer of the share by the deceased shareholder prior to his or her death, or by the bankrupt shareholder prior to the occurrence of the bankruptcy. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">23.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any person or entity that has become entitled to a share as the result of the death or bankruptcy of a
shareholder shall also be entitled to the same dividends and other rights to which said person or entity would have been entitled, had said person or entity been the registered holder of said share. However, prior to being registered as a
shareholder, said person or entity shall not be entitled, with respect to said share, to benefit from any right which is granted to shareholders with regard to General Meetings of shareholders in the Company. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="appb730888_9"></A><U>Increase and Issue of the Registered Capital</U> </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">24.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall be entitled, from time to time, pursuant to a resolution to be passed by the General Meeting
of shareholders, subject however to the provisions of these Articles, to increase the share capital of the Company, by means of such type and in such amount, which shall be divided into shares of such par value, as shall be determined in the
resolution as stated above. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Without derogating from any special rights or privileges which are granted to any existing shares in the share
capital of the Company, the new shares shall be issued pursuant to such terms, subject to such reservations, and in accordance with such advantages and rights as shall apply to those shares, all subject to the provisions of these Articles and as set
forth in the resolution concerning the issue thereof. Subject to the provisions of these Articles, the Company shall be entitled to issue shares with preferred rights, deferred rights or limiting rights with regard to dividends, the return of
capital, or participation in surplus assets or otherwise with special rights or without special rights, including with or without voting rights. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">25.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall not be obligated to offer any new shares whatsoever to the holders of existing shares of any
type and kind. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">26.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless otherwise set forth in the terms of issue of the shares, or in the provisions of these Articles, any
capital which shall be obtained by means of the creation of new shares shall be deemed to constitute part of the original share capital, and shall be subject to the provisions of these Articles in all matters concerning calls for payment and
installments in connection therewith, transfer, endorsement, forfeiture, encumbrance and the like. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="appb730888_10"></A><U>Change in the Registered Capital</U> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">27.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall be entitled, from time to time, pursuant to a resolution to be passed by the General Meeting
of shareholders: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To consolidate its share capital or any part thereof, and to divide it into shares of par value per share which
is higher than that of its existing shares; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To subdivide its existing shares, in whole or in part, into shares of par value per share which is lower than
that of its existing shares, subject to that set forth in the provisions of the Companies Law; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To cancel shares with respect to which, as at the date of said resolution, no obligation including a contingent
obligation on the part of the Company to issue such shares exists, and to reduce the share capital by the amount of the shares canceled as set forth above; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reduce the share capital of the Company and any capital fund, by any means which it shall see fit, subject
to all of the conditions and approvals which shall be required by any law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">28.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">With respect to any consolidation of issued shares into shares of larger nominal value, and with respect to any
other action which may result in fractional shares, the Board of Directors may settle any difficulty which may arise with regard thereto as it deems fit and in its sole discretion. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="appb730888_11"></A><U>C. GENERAL MEETINGS</U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">29.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall hold two types of General Meetings of its shareholders: &#147;<B>Annual Meetings</B>&#148;
and &#147;<B>Special Meetings</B>&#148;: An Annual Meeting shall be convened once a year, on a date which shall be set by the Chair of the Board of Directors or by the Company Secretary, but no later than 15 months after the last Annual Meeting, and
in a place which shall be determined by the Chair of the Board of Directors or by the Company Secretary. All of the other General Meetings of the Company shall be referred to as &#147;Special Meetings&#148; (Annual Meetings and Special Meetings
shall be collectively referred to herein as &#147;<B>General Meetings</B>&#148;). All of the in person General Meetings of the Company shall be convened in Israel, unless the Company&#146;s center of management shall have been transferred to another
country in accordance with the provisions of these Articles, provided however that General Meetings may be conducted in other formats (in lieu of or in addition to in person meetings), including a virtual format. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">30.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Whenever the Board of Directors shall see fit, it shall be entitled to convene a Special Meeting according to
its resolution. In addition, the Board of Directors shall convene such a meeting as required under applicable law, provided however, that a demand by a shareholder to convene a Special Meeting shall comply with all of the requirements of a
&#147;Proposal Request&#148; set forth in Article 33(b) (with the demanding shareholder being considered a &#147;Proposing Shareholder&#148; for this purpose); and, should the Board of Directors fail to do so, the demanding director(s) or
shareholder(s) shall be entitled to convene the meeting themselves, pursuant to the provisions of the Companies Law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">31.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall not be required to deliver personal notices (&#145;Hodaa&#146;) of a General Meeting or of
any adjournment thereof to any shareholder. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">32.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Without derogating from the provisions of Article 31 above, the Company will publish its decision to convene a
General Meeting in any manner reasonably determined by the Company, including, without limitation, by publishing a notice on its website, in one or more daily newspapers in Israel or in one or more international wire services, by filing the proxy
with the U.S. Securities and Exchange Commission, and any such publication shall be deemed to have been duly given and delivered on the date of such publication. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The accidental omission to give notice of a General Meeting to any shareholder, or the <FONT
STYLE="white-space:nowrap">non-receipt</FONT> of notice by any shareholder, or any flaw in the conduct of a General Meeting, shall not invalidate the proceedings, or any resolution passed, at any General Meeting. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="appb730888_12"></A><U>Deliberations at General Meetings</U> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">33.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The function of the Annual Meeting shall be as set forth in the Companies Law. Any other matter which is
discussed at an Annual Meeting, and any matter which is discussed at a Special Meeting, shall be deemed a special matter. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each shareholder who is entitled pursuant to applicable law to submit a proposal for the agenda of a General
Meeting (&#147;<B>Proposing Shareholder</B>&#148;) may request, subject to applicable law, that the Board of Directors include a proposal on the agenda of a General Meeting to be held in the future (a &#147;<B>Proposal Request</B>&#148;), provided
that the Proposal Request complies with all the requirements of these Articles, including this Article 33(b) and any applicable law and stock exchange rules, in Israel or abroad. Any such Proposal Request shall be delivered, in person or by
certified mail, to the Company&#146;s Registered Office. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Proposal Request shall set forth (i)&nbsp;the name, business address, telephone number and fax number or
email address of the Proposing Shareholder (or each Proposing Shareholder, as the case may be) and, if an entity, the name(s) of the person(s) that controls or manages such entity, (ii)&nbsp;the number of Ordinary Shares held by the Proposing
Shareholder, directly or indirectly, and, if any of such Ordinary Shares are held indirectly, an explanation of how they are held and by whom, and, if such Proposing Shareholder is not the holder of record of any such Ordinary Shares, a written
statement from the holder of record or authorized bank, broker, depository or other nominee, as the case may be, indicating the number of Ordinary Shares the Proposing Shareholder is entitled to vote as of a date that is no more than
10&nbsp;(ten)&nbsp;days prior to the date of receipt by the Company of the Proposal Request, (iii)&nbsp;any agreements, arrangements, understandings or relationships between the Proposing Shareholder and any other person with respect to any
securities of the Company or the subject matter of the Proposal Request, (iv)&nbsp;the Proposing Shareholder&#146;s purpose in making the Proposal Request, (v)&nbsp;the complete text of the resolution that the Proposing Shareholder proposes to be
voted upon at the General Meeting, (vi)&nbsp;a statement signed by the Proposing Shareholder of whether the Proposing Shareholder has a personal interest in the proposal and, if so, a description in reasonable detail of such personal interest,
(vii)&nbsp;if the proposal is to nominate a candidate for election to the Board of Directors at an Annual Meeting, the Proposal Request shall also include (A)&nbsp;a declaration signed by the nominee and any other information required under the
Companies Law, (B)&nbsp;to the extent not otherwise provided in the Proposal Request, information in respect of the nominee as would be provided in response to the applicable law, regulation and/or stock exchange rules, including disclosure
requirements in Israel and/or abroad, (C)&nbsp;a representation made by the nominee of whether the nominee meets the objective criteria for independence under any applicable law, regulation or stock exchange rules, in Israel or abroad, and if not,
then an explanation of why not, (D)&nbsp;details of all relationships and understandings between the Proposing Shareholder and the nominee, and (E)&nbsp;a statement signed by the nominee that he or she consents to be
</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
named in the Company&#146;s notices and proxy materials relating to the General Meeting, if provided or published, and, if elected, to serve on the Board of Directors, and (viii)&nbsp;any other
information required at the time of submission of the Proposal Request by applicable law, regulations or stock exchange rules, in Israel and/or abroad. In addition, the Proposing Shareholder shall promptly provide any other information reasonably
requested by the Company. The Company shall be entitled to publish any information provided by a Proposing Shareholder pursuant to this Article 33(b), and the Proposing Shareholder shall be responsible for the accuracy thereof. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">34.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Two shareholders who are present at a General Meeting, in person or by proxy or represented by their Authorized
Persons, and who jointly hold twenty-five percent or more of the <FONT STYLE="white-space:nowrap">paid-up</FONT> share capital of the Company, shall constitute a legal quorum. No matter shall be discussed at any General Meeting unless a legal quorum
is present at said meeting at the time of commencement of the deliberations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">35.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Should no legal quorum be present half an hour after the time set for the General Meeting whether said meeting
is an Annual Meeting or a Special Meeting the meeting shall be adjourned to one week from that day, at the same time and at the same place, or at another date, time and place as shall be set forth by the Board of Directors in a notice to all of
those persons who are entitled to receive notice of General Meetings. Should no legal quorum be present at the adjourned meeting as well, half an hour after the time set for said meeting, any two shareholders present, in person or by proxy, who
jointly hold twenty percent or more of the <FONT STYLE="white-space:nowrap">paid-up</FONT> share capital of the Company shall constitute a legal quorum and shall be entitled to deliberate all of the matters for the purpose of which the meeting was
convened. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">36.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Chair of the Board of Directors, or, in his or her absence, any other person who has been appointed for
that purpose by the Board of Directors, shall serve as Chair at any General Meeting. Should there be no Chair as stated above, or should he or she not have arrived at the meeting thirty minutes after the time set for said meeting, or should he or
she not desire to serve as Chair of the meeting, any director present, and if no directors are present, the CEO or any other office holder, shall be the Chair, and only if none of the above are present, the shareholders present shall elect another
person from among themselves, and that person shall be the Chair. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">37.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Chair shall be entitled, with the consent of a General Meeting which is attended by a legal quorum, to
adjourn the meeting from time to time and from place to place. However, in the course of the adjourned meeting as stated above, there shall be no deliberation on matters other than those which could have been discussed at the meeting in the course
of which it was decided to adjourn. No shareholder shall be entitled to receive any notice with regard to the adjournment or with regard to the matters which are on the agenda of the adjourned meeting. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">38.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At any General Meeting, resolutions shall be voted upon and adopted by a show of hands, unless a vote by ballot
is demanded whether before or after the announcement of the results of the voting by a show of hands, by the Chair or by at least two shareholders who are present, or by one or more shareholders who are present, in person or by proxy, and who hold
at least five percent of the <FONT STYLE="white-space:nowrap">paid-up</FONT> share capital of the Company. Unless a vote by ballot has been demanded as stated above, the announcement by the Chair that the resolution has been adopted, or has been
adopted unanimously or by a certain majority, or has been rejected, or has not been adopted by a certain majority, and a comment registered to that effect in the minutes kept by the Company, shall constitute prima facie evidence thereof, and there
shall be no need to prove the number of votes or the relative quota of votes in favor or against said resolution. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">39.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Without derogating from that set forth above, resolutions of the General Meeting, on any subject whatsoever,
may also be adopted by way of a vote in writing, which shall be expressed in the following form or in any other form which shall be approved by the Board of Directors or which shall be set forth pursuant to the Companies Law: </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&#147; </B><U>TEVA PHARMACEUTICAL INDUSTRIES LIMITED</U> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I, the undersigned,
<U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U> of
<U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U>, in my capacity as a shareholder of Teva Pharmaceutical Industries Limited, do hereby vote in writing, with
<U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U> ordinary shares which are registered in my name, at the General Meeting of shareholders in the Company which shall take
place on the <U>&nbsp;&nbsp;&nbsp;&nbsp;</U> day of the month of <U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U> in the year
<U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U> and at any adjourned meeting, with regard to the proposed resolutions which are set forth below, as follows:
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:4%;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:15pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:4%;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Signed this day, the <U>&nbsp;&nbsp;&nbsp;&nbsp;</U> day of the month of
<U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U> in the year
<U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U>.&#148; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">40.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Should a vote by ballot have been duly demanded, the voting shall be held at such a time and in such a place as
the Chair shall instruct, and it shall be permissible to hold the voting immediately, or after recess or an adjournment. The results of the vote by ballot shall be deemed as a resolution of the General Meeting with regard to which the vote by ballot
was demanded. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">41.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The demand for a vote by ballot shall not impede the continuation of the meeting for the purpose of
deliberation of any matter which is on the agenda, with the exception of the matter with regard to which the vote by ballot was demanded. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">42.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A vote by ballot for the purpose of electing the Chair of the meeting shall be neither demanded nor conducted.
A vote by ballot with regard to the adjournment of the meeting, if demanded, shall be conducted immediately. A vote by ballot which has been demanded with regard to any other matter shall be held at such a time as the Chair of the meeting shall
instruct. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">43.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Should the votes in favor and against be tied, whether the voting is by a show of hands or by ballot, the Chair
of the meeting shall be entitled to an additional casting vote. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">44.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any resolution of the Company which is adopted at a General Meeting shall be deemed a resolution duly adopted
if it has been adopted by simple majority of the participating votes, as long as there is a legal quorum at said meeting, unless another majority is required pursuant to the Companies Law or to these Articles. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="appb730888_13"></A><U>Votes by the Shareholders</U> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">45.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to, and without derogating from, the existing rights or limitations with regard to any specific type of
shares which constitute part of the Company&#146;s capital, each shareholder irrespective of whether the voting is by a show of hands or by ballot shall be entitled to one vote with respect to each share held by him or her. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">46.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the case of joint holders of a share, either of the registered shareholders who is present, in person or by
proxy, at a General Meeting is entitled to vote at that meeting as if he or she were the sole holder of the shares jointly registered as stated above. However, should two or more joint shareholders be present, themselves or by proxy, at any General
Meeting, the vote of the partner whose name is listed first in the Register shall be the sole allowable vote, and that partner alone shall be entitled to vote, whether in person or by proxy, with respect to the share jointly registered as stated
above. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">47.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shareholders who are eligible to vote may do so in person or by proxy or by way of a vote in writing, and
if the shareholder is a corporation through an empowered person who shall have been duly appointed for the purpose (&#147;<B>Authorized Person</B>&#148;). The document of appointment of a
</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
proxy shall be drawn up in writing and signed by the appointing person or by that person&#146;s agent who shall have been duly appointed in writing for that purpose. If the shareholder is a
corporation, the authorization of an Authorized Person shall be drawn up in writing and signed pursuant to the charter documents of the appointing corporation. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">48.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">One person may be appointed as proxy for several shareholders. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">49.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A proxy or an Authorized Person may also be a person who is not a shareholder in the Company.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">50.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A document of appointment of a proxy, a power of attorney, a vote in writing, a certificate of ownership or any
other document pursuant to which a document of appointment, a vote in writing, or a certificate of ownership is signed, or a copy of any such document, shall be delivered to the Company at the place and time as shall be determined by the Board of
Directors or the Company Secretary from time to time. Should this not be done, the document as set forth above shall not be valid unless otherwise decided by the Chair of the meeting. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">51.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Should a proxy or an Authorized Person vote in accordance with the terms of his or her document of appointment,
his or her vote shall be valid, even if, prior to the voting, the person who appointed the proxy or the Authorized Person dies or becomes legally incompetent, or the appointment is canceled, or the share by virtue of which the proxy or the
Authorized Person voted is transferred to another person, unless notice in writing with regard to the death, legal incompetency, cancellation or transfer as set forth above, shall have been given, prior to the voting to the Company Secretary or to
the Chair of the meeting at which the voting took place. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">52.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A shareholder who is incompetent, or with regard to whom a court of law which is competent to do so has issued
a guardianship order, shall be entitled to vote, whether by a show of hands or by ballot, through his or her guardian or through another person, fulfilling the role of such a guardian, who has been appointed for this purpose by a court of law as
stated above, and any such guardian or other person as stated above shall be entitled to vote whether personally or by proxy. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">53.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The document of appointment of a proxy or an Authorized Person shall be drawn up in the following form or in
any other form which shall be approved by the Board of Directors or the Company Secretary. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>&#147;TEVA PHARMACEUTICAL
INDUSTRIES LIMITED </U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I, the undersigned,
<U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U> of
<U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U>, in my capacity as a shareholder of Teva Pharmaceutical Industries Limited, do hereby appoint
<U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U> of
<U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U> as my proxy, to vote in my name and in my stead, at the General Meeting of shareholders in the Company which shall take
place on the day of the month of <U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U> in the year and at any adjourned meeting. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Signed this day, the <U>&nbsp;&nbsp;&nbsp;&nbsp;</U> day of the month of
<U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U> in the year
<U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U>,
<U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U>
<U></U><U></U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;
&nbsp;&nbsp;&nbsp;</U><U> </U>&#148; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="appb730888_14"></A><U>D. THE BOARD OF DIRECTORS</U> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">54.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The maximum number of Directors of the Company shall be 18 (eighteen) Directors. Such maximum number includes
the two external Directors, to the extent appointed pursuant to the provisions of the Companies Law, and the CEO, as long as he or she serves as a Director in accordance with Article 56(a), and in the event the external directors and/or CEO are not
appointed to the Board of Directors, such maximum number of Directors shall be reduced accordingly. The Board of Directors is entitled, at any time and from time to time, to change the maximum number of Directors as stated above, by a majority of
three-quarters of the persons voting. Should the Board of Directors have changed the number of Directors as set forth above, the number of members of each of the groups set forth in Article 56(b) below shall be changed accordingly.
</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The minimum number of Directors on the Board of Directors shall be 3 (three). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">55.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board shall consist of a meaningful representation of Israeli resident directors, which need not be a
majority, unless the Company&#146;s center of management shall have been transferred to another country in accordance with the provisions of these Articles. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="appb730888_15"></A><U>Appointment and Retirement from Office</U> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">56.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The CEO shall serve as a member of the Board of Directors, <FONT STYLE="white-space:nowrap">ex-officio,</FONT>
unless determined otherwise by the Board of Directors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board of Directors shall be divided into 3 (three) classes, as nearly equal in number as possible, each
serving for approximately a three-year-term. At each Annual Meeting, up to 5 (five) Directors, the exact number to be determined by the Board of Directors at its sole discretion, shall be elected to hold office until the third Annual Meeting which
shall be held following the Annual Meeting at which they are elected. The provisions of this Article shall not apply to the CEO, who serves as a member of the Board of Directors by virtue of the provisions of subsection (a)&nbsp;above, in the event
that he or she so serves, nor to the two external Directors to the extent appointed pursuant to the provisions of the Companies Law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The nomination of candidates for election as Directors shall be made by the Board of Directors (in accordance
with the recommendations of the Nominating Committee appointed by the Board of Directors). A shareholder interested in proposing the nomination of certain candidate(s) for consideration by the Nominating Committee as aforementioned shall submit his
or her proposal in writing to the Company&#146;s Registered Office in accordance with the requirements of applicable law. Any proposal by a shareholder as set forth above shall include all of the information required by Article 33(b).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Should the number of members of any class of such 3 (three) classes become less than the maximum number of
members at such time, the Board of Directors shall be entitled, at any time and from time to time, to appoint, within the framework of the maximum number as stated, Directors who shall serve until the expiry of the term of office of the members of
the class in question. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">57.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Directors who are serving in office shall be entitled to act even if a vacancy occurs on the Board of
Directors. However, should the number of Directors, at the time in question, become less than the minimum set forth in these Articles, the remaining Directors or the remaining Director shall be entitled to act for the purpose of filling the
vacancies which shall have occurred on the Board of Directors or of convening a General Meeting, but not for any other purpose. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">58.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any Director who shall have retired from his or her office shall be qualified to be <FONT
STYLE="white-space:nowrap">re-appointed&#151;unless</FONT> a limitation affecting his or her appointment as a Director shall exist pursuant to the provisions of the Companies Law. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">59.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The office of a Director shall fall vacant, prior to the expiry of his or her term in office, only:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If he or she has been removed from office pursuant to Article 60 below; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For any reason mandated by applicable law. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board of Directors shall be entitled to appoint, as a replacement for a Director whose office has fallen
vacant pursuant to the mandatory provisions of the Companies Law, another Director, who shall serve in office until the date on which the term in office of his or her predecessor would have expired, had said office not fallen vacant as stated.
</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any person or persons who are competent to appoint and/or to elect a Director pursuant to the provisions of
these Articles shall be entitled to determine that the said appointment/election shall enter into force at some future date. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">60.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Should any Director violate a duty of care or a duty of loyalty to the Company, the General Meeting shall be
entitled to remove that Director from office prior to the expiry of his or her term in office (a &#147;<B>Removed Director</B>&#148;), provided that the Removed Director shall be given a reasonable opportunity to state his or her case before the
General Meeting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Should a Director have been removed from office as set forth in subsection (a)&nbsp;above, the General Meeting
shall be entitled, in the same session, to elect another Director in his or her stead. Should it fail to do so, the Board of Directors shall be entitled to do so, pursuant to the provisions of Article 56(d) above. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any Director who shall have been appointed by way of a resolution as stated in subsection (b)&nbsp;above, shall
serve in office for the period remaining of the term in office of the Removed Director and shall be qualified to be <FONT STYLE="white-space:nowrap">re-appointed.</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="appb730888_16"></A><U>Remuneration of Directors</U> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">61.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The remuneration of the Directors, including in connection with the performance of special duties or services
over and above his or her regular duties as a Director, shall be determined in accordance with applicable law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Director shall be entitled to perform another duty or to hold another office in the Company (except for the
office of Accountant, Internal Auditor or attorney for the Company) on a salaried basis, in addition to his or her duties as a Director, pursuant to such terms, with regard to salary and other matters, as shall be determined in accordance with
applicable law. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="appb730888_17"></A><U>Powers and Duties of the Board of Directors</U> </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">62.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board of Directors shall formulate Company policy and shall supervise the performance of the duties and
operations of the CEO. Any power of the Company which has not been conferred upon another organ pursuant to the Companies Law or to these Articles may be exercised by the Board of Directors. However, this power of the Board of Directors shall be
subject to the provisions of these Articles and the provisions of the Companies Law, provided that no provision which shall be enacted by the Company shall revoke the validity of any action which had previously been taken by the Board of Directors
and which would have been legal, had it not been for that set forth in this Article. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U><A NAME="appb730888_32"></A>Operations of
the Board of Directors </U></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">63.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board of Directors shall meet for the purpose of conducting its business, and shall be entitled to adjourn
its sessions from time to time and to establish the procedure of said sessions as it shall see fit. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">64.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any question which shall arise in any of the sessions of the Board of Directors shall be settled by simple
majority of all of the Directors who are voting at that session, unless otherwise set forth by another provision of these Articles. Should the votes be tied, the Chair of the Board of Directors shall be entitled to an additional casting vote.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">65.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The legal quorum which shall be required for a session of the Board of Directors shall be a majority of the
members of the Board of Directors then serving in office, but shall not be fewer than three Directors, unless otherwise determined in these Articles. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">66.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At any session of the Board of Directors at which a legal quorum is present, the participants in that session
shall be entitled to exercise all of the powers which are vested in the Board of Directors. A Director who has a personal interest in any matter on the agenda, shall be considered present for quorum purposes. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">67.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board of Directors shall be entitled to elect a Chair of the Board of Directors and to determine his or her
term in office, provided that the CEO shall not serve as Chair of the Board of Directors other than pursuant to the provisions of the Companies Law, provided that the CEO serves as a Director at the same time and throughout the period he serves as
Chairman of the Board. Should the Board of Directors not determine the term in office of the Chair of the Board of Directors and until otherwise resolved by the Board of Directors, said Chair shall serve for as long as he or she serves as a
Director. Should no Chair of the Board of Directors be elected, or should the Chair not be present at any session within 30 minutes after the time set for said session, the Board of Directors shall select one of its members who shall serve as Chair
of the session. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">68.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Chair of the Board of Directors shall be entitled to convene a session of the Board of Directors at any
time and pursuant to the provisions of the Companies Law, or according to a request by the CEO. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Should the Chair of the
Board of Directors fail to convene a session of the Board of Directors within 21 days of the date on which a demand was presented to him or her by any person entitled to present a demand as stated above (&#147;<B>Demanding Party</B>&#148;), or
within 21 days of the date on which he or she shall have been demanded to do so pursuant to the provisions of the Companies Law, any one of the Demanding Parties shall be entitled to convene a session of the Board of Directors pursuant to the
provisions of the Companies Law. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">69.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notice of sessions of the Board of Directors shall be sent by mail, or shall be delivered by hand or by fax or
by telephone or by email or by any other medium of communications to all of the Directors, a reasonable time before the applicable session, unless otherwise provided by the Companies Law. Said notice shall include a reasonable level of detail with
regard to the subjects on the agenda. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">70.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Failure to send notice to any Director with regard to a session of the Board of Directors, due to error, shall
not adversely affect the validity of any resolution which shall have been adopted by the session in question. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">71.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A majority of the <FONT STYLE="white-space:nowrap">in-person</FONT> sessions of the Board of Directors each
year shall be convened in Israel, unless otherwise determined by the Chair of the Board of Directors at his sole discretion, or in the event the Company&#146;s center of management shall have been transferred to another country in accordance with
the provisions of these Articles. Notwithstanding the above, the Board of Directors shall be permitted: (i)&nbsp;to hold sessions through the use of any means of communication, provided that all the participating Directors can hear each other
simultaneously; and (ii)&nbsp;to adopt resolutions without convening a session, provided that this method of adoption without convening a session for this purpose shall be approved by all of the Directors who are eligible to participate in the
deliberations and to vote on the matter addressed by the resolutions and that the resolutions themselves shall be adopted by the applicable majority of Directors required by the Companies Law and these Articles. Should resolutions be adopted without
convening a session as stated in subsection (ii)&nbsp;above, the Chair of the Board of Directors (or a designee of the Chair) shall sign the minutes pertaining to the resolutions, and there shall be no need to append the signatures of the remaining
Directors to said minutes. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="appb730888_18"></A><U>Committees of the Board of Directors</U> </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">72.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the provisions of applicable law, the Committees of the Board of Directors shall be composed of such
number of Directors as shall be determined by the Board of Directors. Subject to the provisions of the Companies Law, the Chair of the Board of Directors shall be entitled, from time to time, to join any Committee of the Board of Directors, as a
member of said Committee. The Board of Directors shall be entitled, from time to time, to delegate any of its powers to the Committees of the Board of Directors. Notwithstanding, the Board of Directors shall not be entitled to delegate any of its
powers to the Committees as stated above, other than for the purpose of recommendation only, with regard to those matters which may not be delegated by the Board of Directors under the Companies Law. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the provisions of the Companies Law, a transaction between the Company and an Officer or a
transaction between the Company and another entity in which an Officer of the Company has a personal interest according to Section&nbsp;270(1) of the Companies Law, which is not an extraordinary transaction (as such term is defined in the Companies
Law), can be approved by the Board of Directors or by a Committee of the Board of Directors authorized by the Board of Directors for such purposes, or according to Company policy approved by the Board of Directors or such Committee of the Board of
Directors. The approval may be for a particular transaction or more generally for certain types of transactions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any Committee which has been composed as stated above shall be obligated, when making use of the powers vested
in it, to comply with all of the rules which shall be set forth by the Board of Directors. The office of a member of a Committee shall fall vacant upon the termination of the member&#146;s office as a Director, upon his or her resignation from the
Committee or upon his or her removal by the Board of Directors from the Committee for any reason. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">73.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board of Directors shall be entitled to appoint, for each Committee of the Board of Directors, a permanent
Chair from among the members of that Committee. Should the Chair not be present within 30 minutes of the time set for a Committee session, or should there be no Chair of the Committee, those present at the session shall be entitled to elect a member
from among themselves who shall serve as Chair of the session. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">74.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The provisions of these Articles with regard to the sessions and procedures of the Board of Directors shall
also apply, <I>mutatis mutandis</I>, to sessions of any Committee of the Board of Directors, with the exception of the provisions of the closing passage of Article 64 and the opening passage of Article 71, unless otherwise determined in the
Companies Law or in these Articles. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="appb730888_19"></A><U>Signature and Minutes</U> </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">75.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall appoint, from time to time, a person whose signature, or persons whose signatures, together
with the stamp of the Company or the printed name of the Company, shall bind the Company. This shall apply, whether generally or to a specific matter or specific matters, as shall be determined by the Company. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">76.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The minutes of any session of the Board of Directors and any session of a Committee of the Board of Directors,
provided that they shall appear to have been signed by the Chair of that session or by the Chair of the subsequent session of the same entity, shall be deemed to constitute prima facie evidence of the correctness of all of the matters set forth
therein. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">77.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All of the operations which are performed in good faith by the Board of Directors or by a Committee of the
Board of Directors, or by any person acting as a Director, shall be valid even if </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
it shall subsequently be found that there was a deficiency in the appointment of such an entity or of such a Director, or if any or all thereof shall be deficient, just as if each of said entity
or Director had been duly appointed and had been qualified to act, as required by the circumstances of the case at hand. </TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="appb730888_20">
</A><U>E. CEO</U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">78.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board of Directors shall appoint, from time to time, a person who shall serve as the CEO of the Company,
for such a duration and pursuant to such terms, including terms with regard to remuneration and/or benefits, as the Board of Directors shall see fit. </P></TD></TR></TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board of Directors is entitled to terminate the term in office of the CEO, at any time and for any reason
whatsoever. </P></TD></TR></TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The CEO will lead the management team and manage the Company from its headquarters in Israel, unless the
Company&#146;s center of management shall have been transferred to another country in accordance with the provisions of these Articles. </P></TD></TR></TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The CEO shall be responsible for the day to day management of the affairs of the Company, within the framework
of the policy that has been set forth by the Board of Directors, subject to its guidelines, and all in accordance with the provisions of the Companies Law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">79.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board of Directors shall be entitled, from time to time, as it shall see fit, to delegate to the CEO any of
the powers which have been vested in the Board of Directors, with the exception of those which have been exclusively conferred upon the Board of Directors and may not be delegated pursuant to the provisions of the Companies Law. Moreover, the Board
of Directors shall be entitled, from time to time, to restrict the delegation of powers, both with regard to the duration thereof and with regard to the purposes for which they shall be used, and to limit them to specific areas and to make them
contingent upon specific conditions, all as the Board of Directors shall see fit. At the time of delegation of powers, as stated above, to the CEO, the Board of Directors shall be entitled to determine that said delegation shall be parallel to, or
shall supplant, the respective operation of the Board of Directors. The Board of Directors shall be entitled, from time to time, to rescind or to modify the delegation of any power which shall have been delegated pursuant to this Article.
</P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="appb730888_21"></A><U>F. DIVIDEND, RESERVE FUND AND CAPITALIZATION</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="appb730888_22"></A><U>Dividend</U> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">80.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall be entitled to distribute a dividend pursuant to the provisions of the Companies Law, and no
dividend shall bear interest; each dividend shall be determined and settled in consideration of the rights of the shareholders, if any, whose shares shall bear special rights with regard to dividends. Unless the rights are attached to any shares or
unless otherwise stated in the terms of issue thereof, shares which have been paid up, in whole or in part, shall entitle the holders thereof to a dividend in a manner proportional to the amount which has been paid up, or credited as having been
paid up, on the par value of said shares and to the date of payment thereof (<I>pro rata temporis</I>). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">81.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board of Directors shall be entitled to declare, and cause the Company to pay, a dividend to the
shareholders. The Board of Directors shall determine the time for payment of such dividend and the record date for determining the shareholders entitled thereto, subject to applicable law. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">82.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board of Directors shall be able to adopt a resolution stating that the dividend in question shall be paid,
in whole or in part, by means of the distribution of cash or other assets of the Company, and in particular, by distribution of fully <FONT STYLE="white-space:nowrap">paid-up</FONT> shares, bonds, or other securities of the Company or of any other
company, or in any other manner. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">83.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The right to a dividend with respect to nominative shares, which has been declared by the Company, shall be
determined in accordance with that recorded in the Register or in an Additional Register as of the date of record, according to the declaration. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">84.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless otherwise specified, it shall be permissible to pay any dividend by check or bank transfer or payment
order, which shall be sent according to the registered address of the shareholder or the person entitled to the dividend (and in the case of joint registered holders, to the shareholder whose name is first mentioned in the Register or in an
Additional Register with regard to the joint ownership), or in any other manner. Any such check shall be drawn up to the order of the person to whom it is sent. The receipt of the dividend by the person who is registered in the Register or in an
Additional Register as the holder of any share or, in the case of joint holders, by any of the joint shareholders shall constitute full, final and absolute release with regard to all payments which shall have been made with respect to said share.
The Company shall be entitled to withhold tax or any other mandatory payment from any dividend payment pursuant to applicable law. The Company shall be entitled to invest all of the dividends which have not been claimed, or to use them in any other
manner, for the benefit of the Company, until said amounts are claimed, and the Company shall not be deemed a trustee or fiduciary in respect thereof. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">85.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any dividend unclaimed after a period of 7 (seven) years from the date of declaration of such dividend shall be
forfeited to the benefit of the Company; provided, however, that the Company, at its sole discretion, shall be entitled to pay any such dividend, or any part thereof, to a person who would have been entitled thereto had the same not been forfeited.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="appb730888_23"></A><U>Reserve Fund</U> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">86.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board of Directors shall be entitled, from time to time, to allocate amounts out of the profits of the
Company which may be distributed in the form of dividends, and to transfer such amounts, as it shall see fit, to an account of a fund or funds as it shall see fit. All of the amounts which shall be so transferred and so credited to the account of
such a fund shall serve, at the discretion of the CEO, after having consulted with the Chief Financial Officer, and subject to the approval of the Board of Directors, for special purposes or for the gradual settlement of any debt or obligation of
the Company or for the repair or maintenance of any of the Company&#146;s assets or for the coverage of losses from the sale of assets or investments or the depreciation in value thereof (whether on a <FONT STYLE="white-space:nowrap">one-time</FONT>
basis or in a general manner), or, at the Board of Directors&#146; sole discretion, for the supplementing or payment of a dividend or for any other purpose which shall be appropriate for use of the Company&#146;s profits. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">87.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All of the amounts which shall have been transferred and credited to the account of any fund or funds may be
used, so long as they have not been used for any other purpose pursuant to Article 86 above, for the purpose of investment, together with any other monies of the Company, in the ordinary course of business of the Company, and there shall be no need
to distinguish between these investments and the investments of other monies of the Company. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="appb730888_24"></A><U>Capitalization</U> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">88.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board of Directors shall be entitled, at any time and from time to time, to adopt a resolution stating that
any part of the amounts which are credited at that time to any capital fund or held by the Company as profits which may be distributed, shall be capitalized and shall be released for distribution among the shareholders who would have been entitled
to receive them, had they been distributed as a dividend, and in the same proportion, provided that said amounts shall not be paid in cash, but shall be used to fully pay up whether according to their par value or with the addition of any premium
which shall be determined by the Board of Directors shares which have not yet been issued or bonds of the Company, </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
which shall be issued and distributed among said shareholders and in such a proportion, as shares or bonds which have been fully paid up. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In any case in which the Company shall issue bonus shares by way of capitalization of profits or funds, at a
time where there shall be in circulation any securities which have been issued by the Company and which confer upon the holders thereof the right to convert said securities to shares in the share capital of the Company or options to purchase shares
in the share capital of the Company (the rights of conversion or the options as stated above shall be referred to as &#147;<B>the Rights</B>&#148;), the Board of Directors shall be entitled (in cases where the Rights, or any part thereof, shall not
be adjusted in any other manner in accordance with the terms of issue thereof) to transfer to a special fund (which shall be referred to by whatever designation shall be resolved by the Board of Directors, and which shall be referred to as
&#147;<B>the Special Fund</B>&#148;) an amount which shall be equal to the nominal amount of the share capital which those persons entitled to all or part of the Rights would have received, as a result of the issue of the bonus shares, had they
exploited their Rights prior to the date of record which sets forth the right to receive bonus shares, including the right to fractions of shares, and, in the case of a second or additional distribution of bonus shares including eligibility which
results from any prior distribution of bonus shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In any case in which the Company shall issue new shares and/or, in lieu of such issue, shall cause its
subsidiary to transfer existing shares in the Company which are held by said subsidiary, as a result of the exploitation of said Rights by the persons entitled thereto, in cases where the Board of Directors implemented a transfer to the Special Fund
with respect to those Rights pursuant to subsection (i) above, the Company shall issue to any such holder, in addition to the shares to which he or she is entitled as a result of the exploitation of his or her Rights, a number of fully <FONT
STYLE="white-space:nowrap">paid-up</FONT> shares whose total par value shall be equal to the amount which was transferred to the Special Fund in respect of his or her Rights. This shall be done by means of capitalization of an appropriate amount
from the Special Fund, and the Board of Directors shall be entitled to decide, at its sole discretion, on the manner of handling the Rights to fractions of shares. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Following any transfer to the Special Fund, should the Rights expire, or should the period set forth for
exploitation of the Rights with regard to which the transfer was implemented come to an end, before said Rights have been exploited, any amount which was transferred to the Special Fund with regard to the aforementioned unexploited Rights shall be
released from the Special Fund, and the Company shall be entitled to handle any amount which shall be so released in any manner in which it would have been entitled to handle said amount, had it not been transferred to the Special Fund.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">89.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the purpose of implementation of any resolution which shall be adopted on the basis of Articles 82 or 88 of
these Articles, the Board of Directors shall be entitled, at its sole discretion, to settle, as it shall see fit, any difficulty (if any) which shall arise with regard to the distribution. To this end, the Board of Directors shall be entitled to
issue partial certificates, to determine the value of the distribution of certain assets, and to determine that shareholders shall receive payment on the basis of the value which shall have been determined as stated above, or that fractions at a
value of less than 0.1 New Israeli Shekel shall not be taken into account, in order to adjust the rights of the parties. In addition, the Board of Directors shall be entitled to place all monies and specific assets in trust, in the hands of
trustees, on behalf of those persons who are entitled to receive the dividend or the monies which have been capitalized, all as the Board of Directors shall see fit. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="appb730888_25"></A><U>G. AUDITING AND NOTICES</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="appb730888_26"></A><U>Auditing and Internal Auditor</U> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">90.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Annual Meeting shall be entitled to appoint the Accountant, who shall serve for a period which shall not
extend beyond the next Annual Meeting. At least once a year, the Accountant shall audit the Company&#146;s accounts and shall express his or her opinion as to the correctness of the Statement of Profit and Loss and the Balance Sheet. The Board of
Directors shall fix the remuneration of the Accountant for auditing services. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">91.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board of Directors of the Company shall appoint an Internal Auditor, pursuant to the provisions of the
Companies Law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board of Directors is entitled to terminate the term of office of the Internal Auditor, pursuant to the
provisions of the Companies Law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The organizational superiors of the Internal Auditor shall be the CEO jointly with the Chair of the Board of
Directors. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="appb730888_27"></A><U>Notices</U> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">92.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Without derogating from Articles 31and 32 above, the Company shall be entitled to deliver notices to its
shareholders by any of the alternative means set forth hereinafter: delivery by hand; dispatch by mail to the address appearing in the Register or in an Additional Register; dispatch by facsimile to the fax number appearing in the Register or in an
Additional Register, or to any number which shall have been given to the Company for this purpose by any shareholder; dispatch by <FONT STYLE="white-space:nowrap">e-mail</FONT> to the <FONT STYLE="white-space:nowrap">e-mail</FONT> address registered
for that purpose in the Register or in an Additional Register; or in any other manner as shall be determined by the Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">93.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any and all notices which are to be delivered to a shareholder shall be given, with regard to jointly held
shares, to the person whose name is first mentioned in the Register, and any notice thus given shall be deemed sufficient notice to the holders of the share. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">94.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall be entitled to give notice to persons who are entitled to any share as a result of the death
or bankruptcy of the shareholder, by sending said notice by any of the alternative ways set forth in Article 92 above according to the address, fax number or <FONT STYLE="white-space:nowrap">e-mail</FONT> address (if any) given for that purpose by
said persons, or by delivering the notice in the same way in which it would have been delivered (until such details shall have been given), had it not been for the death or bankruptcy as stated above. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">95.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any notice or other document which has been sent in any manner which is permitted pursuant to these Articles
shall be deemed to have been duly given to its destination on the first business day at the receiving end following delivery, if delivered personally, 72 (seventy two) hours after it has been posted (7 (seven) days if sent from Israel to a place
outside Israel, or if sent to Israel from a place outside Israel), on the first business day at the receiving end after transmission by facsimile or <FONT STYLE="white-space:nowrap">e-mail,</FONT> or when actually received by the addressee if
sooner. If a notice is, in fact, received by the addressee, it shall be deemed to have been duly served when received, notwithstanding that it was defectively addressed, or failed in some other respect, to comply with the provisions of this Article.
A declaration in writing, signed by the person delivering the notice or the document, to the effect that a letter containing said notice or said document was addressed to the correct address and duly delivered to a post office, shall constitute
absolute evidence to that effect. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">96.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Failure to send notice to any shareholder pursuant to any applicable law or these Articles or the failure of
any shareholder to receive notice, due to an error or as a result of a mishap beyond the control of the Company, shall not adversely affect the validity of any action, transaction or resolution taken by the Company and/or adopted by the General
Meeting in question. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="appb730888_28"></A><U>H. EXEMPTION, INSURANCE AND INDEMNIFICATION OF OFFICERS</U>
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">97.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the provisions of applicable law, the Company shall be entitled to engage in a contract for
insurance of the liability of any Officer of the Company, in whole or in part, in respect of any liability or expense imposed on an Officer or expended by him or her as a result of any action which was performed by said Officer in his or her
capacity as an Officer of the Company for which insurance may be provided under applicable law, including in respect of any liability imposed on any Officer with respect to any of the following: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Breach of a duty of care
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">vis-&agrave;-vis</FONT></FONT> the Company or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">vis-&agrave;-vis</FONT></FONT> another person; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Breach of a duty of loyalty
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">vis-&agrave;-vis</FONT></FONT> the Company, provided that the Officer acted in good faith and had reasonable grounds to believe that the action in question would not adversely affect
the Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Financial liability which shall be imposed upon said Officer in favor of another person as a result of any
action which was performed by said Officer in his or her capacity as an Officer of the Company; including </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A payment which said Officer is obligated to make to an injured party as set forth in
Section&nbsp;52(54)(a)(1)(a) of the Securities Law and expenses that said Officer incurred in connection with a proceeding under Chapters H&#146;3, H&#146;4 or I&#146;1 of the Securities Law, including reasonable legal expenses, which term includes
attorney fees, or in connection with Article D of Chapter Four of Part Nine of the Companies Law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">98.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the provisions of applicable law, the Company shall be entitled to indemnify post factum and/or
undertake in advance to indemnify any Officer of the Company, as a result of any liability or an expense imposed on him or her or expended by him or her as a result of any action which was performed by said Officer in his or her capacity as an
Officer of the Company, in respect of any liability or expense for which indemnification may be provided under applicable law, including in respect of any liability or an expense imposed on the Officer as follows: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Financial liability imposed upon said Officer in favor of another person by virtue of a decision by a court of
law, including a decision by way of settlement or a decision in arbitration which has been confirmed by a court of law, provided that the undertaking to indemnify in advance shall be limited to events which, in the opinion of the Board of Directors
of the Company, are foreseeable, in light of the Company&#146;s activities at the time that the undertaking to indemnify was given, and shall further be limited to amounts or criteria that the Board of Directors has determined to be reasonable under
the circumstances, and provided further that in the undertaking to indemnify in advance the events that the Board of Directors believes to be foreseeable in light of the Company&#146;s activities at the time that the undertaking to indemnify was
given are mentioned, as is the amount or criteria that the Board of Directors determined to be reasonable under the relevant circumstances, including </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A payment which said Officer is obligated to make to an injured party as set forth in
Section&nbsp;52(54)(a)(1)(a) of the Securities Law and expenses that said Officer incurred in connection with a proceeding under Chapters H&#146;3, H&#146;4 or I&#146;1 of the Securities Law, including reasonable legal expenses, which term includes
attorney fees, or in connection with Article D of Chapter Four of Part Nine of the Companies Law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reasonable litigation expenses, including attorney fees, expended by the Officer as a result of an inquiry or a
proceeding conducted in respect of such Officer by an authority authorized to conduct same, which was concluded without the submission of an indictment against said Officer and without any financial penalty being imposed on said Officer instead of a
criminal proceeding (as such term is defined in the Companies Law), or which was concluded without the submission of an indictment against said Officer with a financial penalty being imposed on
</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
said Officer instead of a criminal proceeding, in respect of a criminal charge which does not require proof of criminal intent or in connection with a financial sanction. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reasonable litigation expenses, including attorney fees, which said Officer shall have expended or shall have
been obligated to expend by a court of law, in any proceedings which shall have been filed against said Officer by or on behalf of the Company or by another person, or with regard to any criminal charge of which said Officer was acquitted, or with
regard to any criminal charge of which said Officer was convicted which does not require proof of criminal intent. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">99.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the provisions of applicable law, the Company shall be entitled, in advance, to exempt any Officer
of the Company from liability, in whole or in part, with regard to damage incurred as a result of the breach of duty of care <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">vis-&agrave;-vis</FONT></FONT> the Company.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">100.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding the foregoing, the Company shall be entitled to insure, indemnify and exempt from liability any
Officer of the Company to the fullest extent permitted by applicable law. Accordingly, (i)&nbsp;any amendment to the Companies Law, the Securities Law or any other applicable law expanding the right of any Officer to be insured, indemnified or
exempted from liability in comparison to the provisions of these Articles shall, to the extent permitted by applicable law, immediately apply to the fullest extent permitted by applicable law, and (ii)&nbsp;any amendment to the Companies Law, the
Securities Law or any other applicable law adversely affecting the right of any Officer to be insured, indemnified or exempted from liability in comparison to the provision of these Articles shall not be in effect post factum and shall not affect
the Company&#146;s obligation or ability to insure, indemnify or exempt from liability an Officer for any act or omission occurring prior to such amendment, unless otherwise provided by applicable law. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="appb730888_29"></A><U>I. MISCELLANEOUS</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="appb730888_30"></A><U>Amendment of the Articles of Association</U> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">101.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall be entitled to modify any of the provisions of this Article and any of the provisions of
Articles 3, 29 (closing passage), 54, 55, 56, 64, 71 (opening passage) and 78 above, by way of a resolution to be adopted at a General Meeting by a majority of eighty-five percent of the votes at that session, unless a lower percentage shall have
been established by the Board of Directors, by a majority of three-quarters of those persons voting, at a session of the Board of Directors which shall have taken place prior to that General Meeting. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall be entitled to modify the remaining provisions of these Articles (which are not included in
the list set forth in subsection (a)&nbsp;above) by way of a resolution to be adopted at a General Meeting by a majority of three-quarters of the votes at that session, unless a lower percentage shall have been established by the Board of Directors,
by a majority of three- fourths of the persons voting, at a session of the Board of Directors which shall have taken place prior to that General Meeting. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="appb730888_31"></A><U>Special Tender Offer</U> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">102.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding that which has been set forth within the framework of the regulations that have been
promulgated by virtue of the Companies Law, a special offer to purchase Company shares shall be governed by the provisions of Sections 328 to 334 of the Companies Law. </P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>teva-20220623.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 6/23/2022 11:56:24 PM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2021-01-31"
  xmlns:teva="http://www.tevapharm.com/20220623"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.tevapharm.com/20220623"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" namespace="http://xbrl.sec.gov/dei/2021" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" namespace="http://xbrl.sec.gov/naics/2021" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="teva-20220623_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="teva-20220623_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.tevapharm.com//20220623/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>teva-20220623_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 6/23/2022 11:56:24 PM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Country</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Country</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>teva-20220623_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 6/23/2022 11:56:24 PM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.tevapharm.com//20220623/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="teva-20220623.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com//20220623/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCountry" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140036736857712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jun. 23, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">TEVA PHARMACEUTICAL INDUSTRIES LTD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">00-0000000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000818686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 23,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">L3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-16174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">124 Dvora Hanevi&#8217;a Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Tel Aviv<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">6944020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">3-914-8213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">American Depositary Shares,each representing one Ordinary Share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TEVA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>d730888d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="teva-20220623.xsd" xlink:type="simple"/>
    <context id="duration_2022-06-23_to_2022-06-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2022-06-23</startDate>
            <endDate>2022-06-23</endDate>
        </period>
    </context>
    <dei:EntityRegistrantName
      contextRef="duration_2022-06-23_to_2022-06-23"
      id="Hidden_dei_EntityRegistrantName">TEVA PHARMACEUTICAL INDUSTRIES LTD</dei:EntityRegistrantName>
    <dei:EntityAddressCountry
      contextRef="duration_2022-06-23_to_2022-06-23"
      id="Hidden_dei_EntityAddressCountry">IL</dei:EntityAddressCountry>
    <dei:EntityTaxIdentificationNumber
      contextRef="duration_2022-06-23_to_2022-06-23"
      id="Hidden_dei_EntityTaxIdentificationNumber">00-0000000</dei:EntityTaxIdentificationNumber>
    <dei:AmendmentFlag contextRef="duration_2022-06-23_to_2022-06-23">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2022-06-23_to_2022-06-23"
      id="Hidden_dei_EntityCentralIndexKey">0000818686</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="duration_2022-06-23_to_2022-06-23"
      id="Hidden_dei_CurrentFiscalYearEndDate_duration_2022-06-23_to_2022-06-23">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType contextRef="duration_2022-06-23_to_2022-06-23">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2022-06-23_to_2022-06-23">2022-06-23</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2022-06-23_to_2022-06-23">L3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2022-06-23_to_2022-06-23">001-16174</dei:EntityFileNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2022-06-23_to_2022-06-23">124 Dvora Hanevi&#x2019;a Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2022-06-23_to_2022-06-23">Tel Aviv</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="duration_2022-06-23_to_2022-06-23">6944020</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2022-06-23_to_2022-06-23">972</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2022-06-23_to_2022-06-23">3-914-8213</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2022-06-23_to_2022-06-23">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2022-06-23_to_2022-06-23">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2022-06-23_to_2022-06-23">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2022-06-23_to_2022-06-23">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2022-06-23_to_2022-06-23">American Depositary Shares,each representing one Ordinary Share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2022-06-23_to_2022-06-23">TEVA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2022-06-23_to_2022-06-23">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2022-06-23_to_2022-06-23">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MIR1-\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%
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M>FR-9V87YTC'?8Q']>5=2(6NF9MYEJ6R!F_236P@R*2*Y U+2X<L-03&IAJ
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M4')O<',O8V]R92YX;6Q02P$"% ,4    " !;@-=4F5R<(Q &  "<)P  $P
M            @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (
M %N UU3>*L@_?P0  %$1   8              " @0T(  !X;"]W;W)K<VAE
M971S+W-H965T,2YX;6Q02P$"% ,4    " !;@-=4GZ ;\+$"  #B#   #0
M            @ '"#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( %N UU27
MBKL<P    !,"   +              "  9X/  !?<F5L<R\N<F5L<U!+ 0(4
M Q0    ( %N UU0<.&7J/P$  #P"   /              "  8<0  !X;"]W
M;W)K8F]O:RYX;6Q02P$"% ,4    " !;@-=4)!Z;HJT   #X 0  &@
M        @ 'S$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M    " !;@-=499!YDAD!  #/ P  $P              @ '8$@  6T-O;G1E
C;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"   B%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d730888d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com//20220623/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d730888d8k.htm">d730888d8k.htm</File>
    <File>d730888dex31.htm</File>
    <File>teva-20220623.xsd</File>
    <File>teva-20220623_lab.xml</File>
    <File>teva-20220623_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d730888d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d730888d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "teva-20220623_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "teva-20220623_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "teva-20220623.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 6,
    "total": 6
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "teva",
   "nsuri": "http://www.tevapharm.com/20220623",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d730888d8k.htm",
      "contextRef": "duration_2022-06-23_to_2022-06-23",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.tevapharm.com//20220623/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d730888d8k.htm",
      "contextRef": "duration_2022-06-23_to_2022-06-23",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.tevapharm.com//20220623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.tevapharm.com//20220623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.tevapharm.com//20220623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.tevapharm.com//20220623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.tevapharm.com//20220623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.tevapharm.com//20220623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.tevapharm.com//20220623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.tevapharm.com//20220623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.tevapharm.com//20220623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.tevapharm.com//20220623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.tevapharm.com//20220623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.tevapharm.com//20220623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.tevapharm.com//20220623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.tevapharm.com//20220623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.tevapharm.com//20220623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.tevapharm.com//20220623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.tevapharm.com//20220623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.tevapharm.com//20220623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.tevapharm.com//20220623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.tevapharm.com//20220623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.tevapharm.com//20220623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.tevapharm.com//20220623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.tevapharm.com//20220623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001193125-22-180042-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-22-180042-xbrl.zip
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M%XI\CBV0 S#MJE*S6@OE< L$76PQK6V:9<C]5(H@,A&(JUX/?:F:_7H:&8,
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M<LDHEN#O[L-1AF-91CG_QKE7SX3!%EMR^'-\"9$B'O*/O8EHH\_6O,ZJS;_
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M@^RC68(OA=$1<Y76_)T1!GXI5,W^U_#S\>@4_#4P=>#CU'@ASL\,A-9$L)P
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MD.*<6KQ)<$L32,-T9G'DV07CD=XHEG:_,U+E!/PEC4L!,P\@UHSP:5+K3A9
M\DB4.TRQMSM&Z1I7I]( 3I,@U\2(O14%C?';H)[7OD!''07VAK=H7L]1Q$2#
MEKA#<3N(V,P/V!@]A?+\L*'6#XWEHN*!*I]^#I1V:(I:[N;X4M%ID6/OI(EV
M;EI#=O2(N"^ADTF@Y)1IS*>0,#I)0Y_GV6186BR\@P[ZICIHDYV@'CFS!^E6
MLLWCKX3%#K.RH#NH*T,<@_^ J Z5JL4Y1@.D2R2UUHJ^F*:1Q7BD4"3U3_19
MWJF)@BVD+HG,+FA\;3C>B,:(LW';'$Y/B$V164^DH!=&3!'RF</UAA^0<D!\
M89&GE-SE;&,I+%ARBZW$>WW= C/X@(D5I+PZ9O",[ECIO9/TW]&CYH!]>L6Q
M$_U7Z(S\RD0AFO<W73']'X)26:119M ]Y_DE#N'*7B]Y%CA@YO9)CH9I3CWH
M-4V :GEID%Z/U;L)OC0&B.3VEP62SF?C$17T4RS7A,W:]P(9J:OSO&#.QBC[
M#')5Y)]IHA0.# Z1*U.0RY@DI;K6/J1)F48ZF[%DF?I%KL%9>Y%79%#2&24.
M=%3Q['"XBY'5N_=9.K;@Q450XNBJ]-FNFET_&S ";RO8G4C"IZ6/3I:S0O'A
MA$TF"CQ+Y"]*O\&L4V*(A)G:A*-+?)XLD%RINM3$0]VO[U-2^VW*?=!7:<-T
MC7R_X:%D<T$,Y25O=^%LK=[D&1Y8DC3#\VX>?=;+W'%+]XYTQBM<.?6ELGE"
M6SWD6P?-&6&CA7E_3]5XA!*!O,&6S+X5>-FZ,,L5V#W@]W'I?IC#0-Q_T3G1
MUIE\"\5;E6UA9JPLL\OSD'*MY;0 J9."=Q--)@@,:F03^&S>.!R/X(WT*R4S
M_RD)S0Q#!7&O($ ZYE@36J,JU86+>9^!V.UG==IK#H^7-BNW)F:NF:I3 L'>
M;(O6:(AWDC&R J]OI+"K5LM;6-9?M53QJX XX;JBFK25L";7G60]PND^E1:"
M]Y4(IAEI*;QBI_X]\7+8SJ;Y9=,2+]19G9JFE#]C3Y4>JU/;L.BXICGVQT9"
M%L?RM8:IW(F-4YB(UV;*"[5 GHN,\PNP*V/5G/.&3.N/,>W,BC@G/8'15A!0
M$+F$^C!1C\T%. C$#BC @I9=[;WPDI=MF=C"R$$15^DZVG&.7IY?T07!UI[6
MZK19^$ @CDM7O^(M&SIX/97K3 P/;&M_I0;1$\G4>91_*3DF7-+RB;X:4J7_
M.!?CEVOWNT#K-O9C7<;+T_EX%"M*N.&)C+LL+45\;2.@UE$&&\1H'ZQ2Y]RA
MBJT-20J>VASGE.=3VKMO:WH1[0O?G!'$7J<REA.6ZH#I?'+;\G:>$*?+-$2Y
MCHKPE%T'/JI[%_/)!',U7Z!I+Y/6>]CH5"ZK7&I/WC 'NSK=-U \.J5,/7"<
MVYL5(V!5CUGC(7R:48S0:*5E;TM($#J.$IQL$WQ"4M=H>J41'$/'C]ME8#:1
M#O'DLDGV>9Z3LRGF  ?!V^K$#U2)/B(_17YH]D%2!!/C&(Y''YF<7:I0X&%_
MYF"?PDX3Q#S\].K>+&'2Y2GUO14\@FB*&S4=["7.,XA(32 2!:DZ@PO_JO.B
MGN\$A[EV?!S./"^ST,JLVAZ7[JVHBMR95:J:--A+7S^"JS-'<TGZ_@I0T$F,
M#@&^6^_&3>1XDL836"'A2 Z[#BPXU (3[%NXL' J)DAP),;790 8R]V5.I+(
MEL=&IG4+K.L"3&V"CE%^PCR5J0 LY,\Z1@0B'4>FL29S,],PR7=S/I3.7OC8
M2@/_*<02VNNYY,-EH5RGFRM5BP@2PQ1;HH^ L0>W2T2SQ2<%=CS42!.%8)J$
M+%DK>4D[2P[2^E*E:;C6:KHK%C*9?5-GRP-[U'+(K54Z].SW4+&K-*S/QN3W
M616%IUQ@N"9?TH*N0TGDY&EN?SW1EU&))21<K3+HS%OKS$WD,#M97>I%S21P
M<SA-#J+3$D_8L"-**DV+"&H(/@CN&^[I*QE(+7*]BB<T21=TH^!6/+X^'-9Q
MNZV._,#GT@TY-, L]29.@&$K@D9&10$ZR^A66PZ0%+#5YTE68T_#M;1,XSE8
MB\ /XNYLUD4T[Z9WIZNG=$&#U4\F5&.^*UUC4]"V^Q\TF(W715J)&DI\MX44
M/9UO3/U_Z.Z9T60T;^U'=&E/N2^YP;;^3&2"^6OG>:.\@ITKVQ*E/;1!Z=Q:
MZ6PLZ1D)?@?EF8%!2PBO&QAA $=XH&7&RW?/QI *O<1^\#9UBU6-$[3X*9M*
M&%7 ?_@-:WA0=5':#=)EG/A*IVKU.'==D8"BQ7PFYY5#D84:DM]QVNBKX?E/
M[EMY(R2F-\.A<1F5TGB=ZT-YV.2>M?N#M'KML#5'K*ALT37(AIV9F(L]U'&%
M?DU+4]W"OW1.Z0 [O[T2V$1^CDGG>1XZ.4G'7W'3C>@ Q?FB4J9D,K^D;']$
M?-<F?$!):[CB%.Z15^2N<;F@BHU#Q_%Z.C#-R1YE65XWP@=,XF%RO$)AW?5X
MOWR>_ C8IZG"HOR6Z]$(%^FN46X=R?+K>UP6'1W"WX$*U,_W T-?WUO9"3YU
M3[ZU",T*="E*?^J]F33I:2=E;<U,%@>:/OTA:GX6DCJ+LF2>UR5C3;B!H2J0
M-Q=D^L^\(&B+\U-XQI\2S9=/N>#//JGO)B2;$G^JW-Y$FDU.S69H((FJUE;E
M9]6"073$UA9%,H^P16^B;%NZRN-GY ZH[F&3*0F2F][7%@Z":V3:UW$.!*Z!
MP[.*[-?(6P,JAV0Y.HN0D[=)6384(OYX)\8F\L3T%R)Z/(VB3]QS1-14ZZS)
M=1="QNA8IO=P/"*.)6F5YFQ[$#VV2$G#(2]ED?#-&I0JZ@MJZ=(F)&<YJ,)+
M&C4V5A0F#..GT8>->S"-F4V*=?.P=+#-\$PTZ]<])$<?]>]WYGYB%#.7)'UZ
M=;+_^R3X^'9R]'[R>O_3R<'KR;O@X'#OT_')T<'^<?#NX/W!R?Z>%#$-S$\_
M0.GA 9_\C!<A9 ?L/9 $'F_[OW'MO^G7%.3^.P= 5MW\RK9*;C5^!05PHBZB
MX"-\-@=;#;3<%-3:01;79570_L9B9S1@8F8W OW1UE>@3O_NJ=: 5--J0_N&
M?LMPF W&6G=C#5?T4/049!5]!A.)W7QQ0%>-,HX,*I7(MO"/OW7:Y/60=>QO
M7D#)1CFD%<H)A'9$ 01'&GO'LUUV)R^EX+ D?#.?F^7S/A#75SH$[%W2)%/W
MSA7V)WJ^NW-_U8V<)Z%*>_[HWR].0;!5H2_877P)B'8R^-=]^C_WN=UAC-W'
M_\#A-Q[SM8V%8\;]$4R'<J,WW+M_\Y;9F,V[(V1,0R7X=>RH1YM(GB8YL(ZP
MBT?ZH8,OH1O$,GX#%\A4FMC,Q,5-#TR#(R"@L!?!Q[! 44]UDLJISUL@14O)
MT+@JE_RY?7HRGZLXB2J5<@R&PW 8<RY+SF.YH65& [:#<>X[MRJ,2[]-2K<O
MV#RK;#:\&4;D6#I/Y)"?NO5VVE3&+R'EFQ&>IU/$B%)DOE"QTNDJ$*0Z<H7,
M))Q:<(OQR$\#S3JKZ;T,B9,:4U^F:N$]2'ZXGA '@PQ_51G>1-:N27/-.R _
M7)4D^+0N)(*3MU0)(\MT_#Z#VQG.UYWQJ/6\54G"!N0AF3G'D\N5JUEE[4&Q
M$[0?1I+>SC(T!A$U"2^6'W[EBHGA%G5X[@V;Z-:;:!,9=BRVJ)D-(<=7TB&(
M6$D(NN 4>&G[INS($DH:BF4WM$)&2?O.[><FY"-;B@'VRS3B_D4XOD$*;RV%
MFUAE,/&)R1H(48N$D21%5\U!!^^.<T=R#N3GH-.06;^57$6!+1.L(3;Y3L,B
M8-M(BR"6%+A)<P;$, 0F:4+ZFS!^F[K/M(Z6YR0.M_+2G$9@JLP=II*-HFI[
M:*C:?B>%(HD=IZIHH&B[X=;=R)($0Q9D&\=TI#!#L>JE%UVCS;L4[778,L2=
M-4NFU">#O HOD-[3V;?984!W]E5-'J:DD+)LQ 4T"IC7/M^Z#S&$N) -UV15
ML(,P+"+GR5QPQP,6[/;;9!-1Z <"78S8+Z%B"[?+NJ2_0$03P30+9L4DB5HP
MJ:2_L&,\TC"IKI.RD_JD8I"!@_*$4]*BR"]5(5W/L+^2S=(9M'1I"O6<,3<@
M4 [85//@7^8&!\9SXKWFJ8_+%EQU PGFH>P,^UEHHP+.(9XQ]UK)/$'4-C.A
MFMQ94EAF#<V7Y>.UZ<UQPU]2R3'>VD5XR]VC%#=^IT;@7V@5TU>+T] 69H*7
MSN]X)!,\F,>W5!Z;BB;O1$FJ-#G3<6<2=83T4/.(_@K<I0@?;J+D;&O+EH2H
MOV*12SBO.B_R^NR<J#3F"VP]BY:K+9!I]N]A ]PMEO%"-9:JT-8"!UP*[/4E
MHKAE/JUU@$7N:/X<:##^F3ORFC08+,S6XRNBRRRH%XXH<]F@QZ,BLH)?>CO#
M*=#1!B.&HZMUY-AY((NT+?_:"0ZZ]Q%6')J-)*A@$7HG5!ZT-L+:[]MT(*<P
M #S-],8Q>25G1IPA==$X# ?(V@?()E8B?,B4:4'&S<RL"$>EG U4YH?6F>[>
M*:?-X)+<7B@V$6P\L39!I[KQX,'NV2Z4D3YBSP>D[5P+RC3(3(?,/-Y$&,9D
MJ?5E7+* +$+Z#)Y;9(H^;%N;@? 73X4P,[\$%PHIUJ3 5[<<-@]UCS;!U/6-
MJ/.)E.ON?2@(M@!TY<)\<>61H.I'>2SONKF,S[VL@9R"*$$W43)N2UJ2:O3[
M>.3!W]W;FAZD[1I/IU(\T14],.1,2H_,/+4;VOM=OZB'B Y56\9#75[9U3YU
MJ&3\:MM^$^$B!GVU_,30VZVK$RN*.AF>#L="W\X=CYR+Z*:V3!)E,PP4]G9*
M9J'/N\L16Y9VY[RRMH[@<[\8[MKV.\2)!)C4-,=)H7P.$@=DR"^K*EW$Z-C/
M] H)AIGAC5/1'C9N@\AT;/#:X"!QQS$>=4]F3*RKG:UOY05-2DD*EQV/H .>
M$*NH.@\E1V7?: KJF0=O"3;U4SNT1=CRBJC75N=B-+6B55]TI8NS:V2&H\I'
M]_#-\L^Z;GVP+VZI:#83T]/1):.Y]5H8,.3>(%8 TB38A<&DC,TO35M5ROLF
M95E3U#0XJ^$V292)U>$SB/1';]> /'" S-%D^E&\Z77\S-_-LSJ=):EIG%=@
MS%D3-MO!ADM(: *W[:R4\;I3@^!6OR[9:[+G#M*CO6G$\OLGR<R1)I@V5<FD
M\H:=>^N=NXE HE61V16F0V=LJZ^FE'O(WK:HM/-86D,ZOWG)Z"<I&>TH%1V/
MVK6B 55"#+6B0ZWH-RE@_#%K144]W?')Q<F<F]2S/K]M.:JNCH$_RTI%\3<J
M3]WD\M.E!:#7!-X]Z3DMW.+$7_Y]31S>4#3XE17.W_MX>KI<]\T?MN)K^==W
M&<%XU'L!&3C=I9S?@;ZC$^3ZR/8CW@E.WNZ#=3,YV@L^O GV#H[V7Y]\.#KV
M0*X]-="#;=;EWFPB0GWP6>]B)^)Y]"69UW.'4<SQ(+MHK,'YW'T6;!$U@5+9
MMKU^)SC&\$KCCM+<2NJ-$0V)S:8*+'MQV(+]/E0VVM,$>E _D-+E@VITMM+-
M/E[O?_#J%RS.DVA[2S:R]0BZ0OJZB\CC)[!XH;83:907%&V3\=*K.&2^W',%
M*7PQ-)YAN;$3GN]K'19R;&K9<CB=2N)ZBE$J&C$8::FT6.DB@"\=6E8Q\GRV
M5#>_1@LAW62J%=+1(O^C0)Q35X(K7BAU[Z^:P#EFQ33M/$>\7?+GKA>@$#P/
M*6YPW_EC:4;P_6OG"O]%8R!TNHSEK,CK1:/)MK/PI]O,8>(4,\I(W+D?('EW
M3)EO8@/N$^:B[%?F?:VLK&P_#+9HQVX/2>[;FWB;6,EDSPA+3)J4$KV>*SA&
ML[-9G39;(<+7W% L0=@^DI96]L#3G(E$4BKPB@B9%S6?JF1ONXJ62/&0=J9&
MQ7/+06\3KSVYX6E>9U5QU9>+;]D)FUI+^-BX61,GG8"'\Y&JI'\EG]/<UWPH
M++S9=MS$BJG!X[J+'A=Z!HWF*)&8I\OZMZSD^%9?[E&;D"0/A>=[/!+=Z\#P
M+-BM-W,XI*_OIO6XS#2,$]VV&<Y@8R<&TS0J2V$*R%14I%>!^JLFY)4V0A%\
MGS-W&%<G8[_UXD+7DU B&YQ,(H5!TA9R&3%&?@]E=B>85.RP-9MJUPLT!QX'
M6TB(O^W%$L@QCZ:5'@*U#UZ"1?4;>"=5R860V*2C4%S"8J$@W"/6T*!)9QXP
M1I*448#G"=RTT5".3"2'U)VJHFW>GW!Z_B]<;-B55,+1D]G3;]HW3M=3"W3%
M[K%7!IZ& 1&J]W'B'ZO4CH_L:QM697U:2E-TT+>\(<3]=F,ETC7*B<'H883$
M021#[ X.?:W8T*#6OJU:FVZH6J/FXL:1F6(W<VRMR/WSF#V+L5\=:L]M M^Q
M.[8\[V,\,NY'H;A_1!QYW/6',A38WR":\Z2JE%NGU/N@;63+\DM1L#JZE/J\
MA6EL7+7?5_I;F/?>*K?IS<GWBS5WG3RZ>X#8,BUG5P2N5=I[I!;6%<+_QB/!
M_RUT#VL'I.O#8[7O=V1+O-FQZ?/DA#3&5/7Y+;%A8K(K^UC!+#H=Z?L* 20L
M[?95[&S;#7?TVDD/93_?6(W$&ZA&G AU9T09@^ID"AD@:\M$$K1](+&0*.N.
MKX]'^K::QT["\BOLL^O&^$7I,!F#QB$6T5Q=YL5G2TCIC<X$_$-G!+:"F+T9
M:PBI+XND,!@,M+VH%(DWNT'"ZSGD]!!/(HR'&LDO:4LS[+:U(Q^;2O?@RQ 3
MQ[-?D&1:3+JY\\"RE^H8+("+L*X#Y&PZK=MA;J?,K(.:I3N;%'J]R!UA#'LV
ML43=O222'W(,Y2B;PU&,;]A"Z;:_ZG_W#A)0!U _'O&,)(9!RHFHTB3AL=:?
M#<AI,KAC,#DB[8X[IW5%_L7,ZU%J2 &&'7O+';N)]?5H9AG1;-!&%!2IEJ/&
MJ09I;F*,#"2SA"7Y5+>M&X^6!+4*=<_8QV Z/MY]P2$MW<DN<MC5P$J="1>N
MV^78#:M[.7_I=HN$;5_+EQP29.M+^282!@RJZRY&Y*U-VM(.,_PO.E"K1O&G
M-6\=94-6KC%?0FK(?;V>-W=4K'Y9)E;+%<G6[@:*U8'++.CT))U3T18=E")U
M[LFC(PU/[C/LZ 7>83AIOJGT/-A Z7DCAC6\.-/48"!1.M8VPE^#= RYNIY8
MD!?GD0XZ5)3$F!+B?W%-^M*<A*BP\.3##LQ\^+4,9);)O+A:!Y++#J)^5M@*
M&EF'WX:/8N*NR1R&!/]P;9R\"W! J.$0O@MY]^2:T"F-$:OS*&:B<ODU^:_T
MBG*\V_#6@.>\:[M\$U-7E-<P)(X:,ZU#91[I@VQR#3U' FY,:[G;>ZE_2[%7
M)UK5K4I,_CPP?=QI0SD.]L\FG2:^->'["#, @CXE#N82 VBSNJH+WN-#O.BV
MGO233:11&Q;UKGG2FD'+#11>)'F*YW@4Q#7W&IFB]B+30W^2YE=16ETU\L1A
M9Q&V5DSCD:N9V*UBM60>[?E8UW3<@ZTH,'3-1^*TZ3L[;,TAZ]%8Q58G-B^W
MRI0HI,@*0ZN>3/@<=&=1U5G"[T_VASLL(M-G*X%C^XT)&93GW3/_#5.=D3 +
MEN\*,$2-\J8EF*V.+>> UFR.61+&)?(GE&!S,\NS,3L:]CY>[L@TT2R8JJ\$
MS7 T^86[:OU4M_.3Y=%[IYXKW@Z6=A$8_.8?W*+N2V$U2,;<#@).CRU;\MC8
M1Z?^/I+&@DWGUB1N%9Q'L9/S=3$2GH/;>: 0#_KRG-J:&;4=G4;;H(*8)Z8@
M!EZ\SISFJD87##4P-_,3-I%W=;!?[IJ?<,)P%V]K5RX>*!1PID"!IGF6B9ZU
MY7VJ(*QFQFJ26JAA%3ZH:>:V)2C1%%D'0'<*PQ&A/QU#I%!G=1H5^E<>.,"C
MOS9U QT0U?7B\8,\_[CV^&0%9$MDU9C%[/<6IH)$?YX;&+1+NK'%;<*U[8#=
M9;5Q,)E2$2REI@\R*9N8P+[!H:"=(,3TQNZ0>VYC6#T"ZQV$'PV'TZA,:-.9
MEK0T-H?$NG.#N$8W(U61_SIL<M?28ZYH![I=F[EF:+U-1@0:U]MEW\U<>6K,
ME8_8$(#X/X(]T4-]935K$"?=7>6PS(+91$+GI>DXW/DUA<#TAE[D(,E7CA%?
MU@L\K$K5=;)1)DRV'S8NRQ=R:MIDV_X'*8+0#2G:M(28S^/2?$7GJ933UPM4
M!%K]%&=1=H/.O+K=COJBBBF\Q9(R%@>!RPS.[HB7N/S@29D6K"NK^PT#T,J\
MI!^[RW+[BR;;KLJBJ5.@XQ,B%>HB_\R+1]3]TE29V!3%;)%%B#%+>9'D=9E>
M";E!]%EE_1.&+,"Q_-Q):M)/B>&>\YI)95?7].AJH)%M@>#?I3T_=2K0AP]8
M@7YP!9N+ 3HD@GF !\?OFFIS4]FT>_<\DH]VX=Q!=\4U0WRQ3/>T+L%D*,O0
MCXEX  @F-!V/J*R78Y5ENRB&M48>J+("*R,I#8O(5,68J40G Y.=Y@[(L%\9
M$(,*9DDU&/^W%M1-Y$7$LU57@'@' UC/)9<M9J;,R<C'ZE,--31)*:C_,IDO
M4F59<^@ L96)[5(9Z1:B>QJ;('RKI9$]!A \IELQF(.N@QS'*7:[X/;V6 F#
M87\Z^]Q&)FNCD*QK 2[*-.(.Z7CWH9SR]IMF4YFFN ?/7W5>U*W^!::^EF%H
M(K_KR)5',<@NL5.)V?-K^#AKEY=Q)9/7&&RFT"25TJY">5&ICG9AKM.Z-LG4
M@"'[AVZT3>20FG"Y[^H-9 A%(G]CHA_F-*"G+N_)- $'IQ*2>WN^="2#R6@2
MU\\]LA8<#9%'XHEEZ KZG,.)GYT[IWB3[K!C* _T@<MA)%W(B.V,X\B)VFIZ
M Q7KUR-5(R\M)N70^/4K[(I-K2]>USC16,E5EHUX"!8&:2.DX*\V"G_:N"!+
M^X5'C:'^6O54-MCH0+HV%W+/(+KXCPV@<ZX<?X@[>.5UY::MSQT*Y?&(QC^/
M?,VSBM,79\"%D_:EOM=9$D:,VT.9TO5+.R.%[,KQS5T8.MDB*RBC;4&Y><DL
M7SE02QP5\CW-[/ OQ?K0FBKRE;IP-#R\CZ7F-9KDT:Q2A:U1%R/?<U%7 &E*
M%OL\H\E&YUA;44UPOA923#VX/L[@[MY:=6YBH??)39T\I@Q0:UGS+."@-K6J
MN;9NPZVJ*;C)Q227 NT#':3%N/AU(IWKM*YY=.W6-<V=KGV6CDG1.+CK3*2H
MA@>[V._&S)5?.Q.!KIU3(#DRMIXPV"5SG>.CZ("I./#REUHIZ=LTVR1N&:CL
M'EV *_(1K,@K#RF;%\R/M6JTCM9MP+/X\0[P[R;= :ZTRJ.XBC?>I*_RX3H+
MTAC2>+06D\"@,]?6F9M(&W#(G8DQ2'RM^%]&VFH.^U[,@E;'=?CZG%+GM$-G
MT1?:1ZCBX/Q>G),LTU>()4SEWY:39:[BI)YSY'P^KS/L"$_#0XW9$5\,?7@Z
MJ6<+/W?!+OT11V-U>MDR(^[':*-(*^<&%9O[Z%1=*!H?V(GX9HP#\'L]2U:P
M])W P2ZY[1Y[NHD%16] "C 3@Y 26&8M0A1==G&]/OID#94=!G%-]U%%88!?
MXQ$1J,:P"TLBIB5JF<XDKX,/;O$M,:PXSA=.]E@/:& Y^YHBNXG8UDDS5+T:
MG0U/9Q-,([/7.%"85)DZ.;KA+S19*-[&O1N6QZ^UKE[E<!/=9YL>F8L\J+K*
M]$;Z+LT>&"FPO-L#G,YX*=BL;.O146$+7I8=T0N<GPHV[_-@*Q&,O\;MF971
MC<[Q9C7GJ2E J2(>CW?T-J,RU"_4#;M6/C_<-,K )(:EY:Y%%46;RF1>I_ Z
MBJ D+\B#VDJ< 9+*<303.PH8R'&)W<P9W@P4)1@-@.MI6NA>.@S1<XN@U96]
MLU/UTI0FV#QG"5D=N3,;&A Y'J%1=&I (A*-HVZNN2;3I(AP%,?PX@X0R9T&
M#FM)M,O] OZ>@Z:_<'V AN)VK!]W7]LW<4ECV^ IP25UY5K=@3C/E0D?C[IF
MO+<6Q<B!(^.K]O465V0J:LCLA]^V=3 (ON)IEAC4@IF%'8I?YS5,([;"$84L
MYRXQ7+*N!*>%-XZP'-SH.%,8X[ W,I043$=Y_!W+KW5&+.[W1"R^"K#UF0&V
M&B;H ='Z]>V6342T#L;H7:O).5Z&K_7!]Z$^VE;J!-<:G:-10%]CJ0!X5SU-
M'#OJ 9; B9<.NR/\=R, 4]A#H?UG+IEHRY2_Q,?DW)'MM\$I*/W+WO:=:X\&
MK"-P>I%J@<%HF-&1'+R%<J]<LI:QO,)$EKR53Q/3&LAXU#N25A-1)]_9@?_T
M^RH0O6*KX*0B)BNI,A&7'#'J,E8]OF5=8.HL5D5;@ :TP!TL[[JNCHG8B17H
M_ZFJ+LFQ=<H&*(>22=L+KM0"-W:M'_'NH.U&WK D>)R;^>4??1@:+W5VS)X#
M+]J#I_>W=K=[WHT?EW "'YZJOL"PZ498XN6^PA9N;%T4AK^(U<P!RMD;CT=P
MY^V0_-R&M]B'B. 8]SIJ-XAJT 8%+/RR&U+F',>J44'M[&*S>&>M4=(]>T?I
M,=.?G.M7AU62@AI&1K(G3'6J[OS"=W.,RI\Q6T?*17ZZV4MUM1 M;W\RM'6[
MHY075@)M,9@4@HE5UDSH&J,C/P4WE#M^7"*"=AY]Q@TA02X'YL?@OO$(9"^I
MN(DXW!RDDFND;=BGJ--&7X+3!D:]SS#!+>(2-5M3RE4%+=9F+G+3$".G,1*%
M,N@>.D)I^7+<,E?ZO5<US@$+BGJ1*8;!*6>;%QT_F=/&7J*"Y$;.F^CF"IP3
M&S;OK3WM?UP15!^5*_4MBY:=+7Y"%X/8449M^-CY(6F+YKG$PCWX?%2Y7DD+
MOM( JK61:3(2#Y;F;5 =<_9@<(62^*#GG9E?A6+4._@X-Y.V%-;);S<>^2^M
M8[U]8+=&/<^P_6Z]_3:QM.MD1>ZH[5HZ%5X$6],%@BO#(.-1E)8YM^0,@Y<'
MK^8U=BTI _Q?<+7+ES\?O HYNVTS?FN'%PPS"M-%.&=<VV&9IMPL<!&5)2PM
M?FR(YQ^9\NE\P1F'CJN>[JY3#$.'HE\\OG:5S-_!Y/"+"7@?ZXP$3<9[UFQ#
MA/N&&W]3R]/\*GY[NK;#:]J#%I)TD[ *&\S,[G?8\BL_4YRO-;L3S.SYHNFD
MZS!7P=QS&6+P_4M,74LBFU,^1ZLX*>T;4#3LG![J>(;,VA Q2Q*8N*9TIFA^
MU$_*XC,?#(&PVV^+32PF.W'2NW+ZK('ESN+FE6L%9T+!QKH%*LYN1,P#0BT,
M-H1RTUU(%5N?)K&A5IB?TN-_U80X\=^'"EXXGN91?JFY@?Z6\"7,".[/>02N
MY31!E L,VZ%HF>8%OE6FN 6HX_#J.+3Q<0FQ4JADL"EOOX<VL?1L8M?>(>NQ
M=9!"\,-FTEF>QXC[7Q;ZZ UX=A41A X$6 ZMB/DR^NCM",YH^FG>*5#%#[-'
M.F*6_9L!J5!L!V_1BZF$G&L''P7">DE2@[%[T'K8957"]VY31<GI4CZ $Q/<
M0I0_=$0.'0 ^5# FP+BW0N&55N_R@\ ,^[,NJ24+_(*1;Y(RY4=0PW&'_SJ6
M"I$ZO7)8?/%D,M]Y1+FP)\C4:2*VIDDQK>>8_)Q:EXY(V!'Y"/=#I;V>L_+@
MT5=P5O0R,GBRUW=Y<)_V$'LO^SM8^[2:(W?WP7"F=)PIFUB3-Q@*=PV0LS0P
MO*ZOVHQL5EP6V70NQR.3 <6N',+*VZS*="D^+3\O?= ,DWGLOM*4Z!3<T5E2
ML8>Y%%-R$S:MAX/4_PA8BQZI3THOLJ\3>4N9 _8_A+J,WA09^RFU\>@2#)TR
M1T+*0=CN7F[\1+3A90)*)U51+/ZZ*4ZI5#0GN>'/O)@=:5[$V)W##\&T+,C)
M;Q?;.''P;UP)TQWLOUZL?9#Q6\AXO,$R[O"NE0MD1D(PK\97QA$UG\+_<012
M%&DTFT5)4;8"TI+YQ<]F1317EWGQV3"$"$R*'$D#-UD#Y1$&#M$O[JZS.L&R
MGTQ)00F7"Z\G^NMA-P<C>FW/:!,K[V\%F^[@</6QU!JO##N(T<Q2;NARFUF5
MO8KAK#]+BYFCYMW@DK0NDPNL/FY0=B\)Q'<"G:])D[$3O,\+E0M/MSR*]O8-
M<.D(-RT2*9V6(<E[\S2& <C">5>FW;@B.DY$'";MZS1LDQ2::1=\9<=8ES@^
MJ1A,DWE"HYF35Z,38!$:A?J:><2$WG,JO</PJ=)(,O,#I").=*T;.F7KNC63
MRB)DB-^@:TY:N'@KBM?LD.9W;:48FO-(6^D:8;)0(0$-<[48<OI%&FEN0#P]
M$"Q\X<2VEQ43W+:H 9XW39C] E<ECY/958<@18;]OKL OV\G.)SH:]#0_EVQ
MO5V#2WBS$^P=_'ZPMW^X%P9'^\?[1[_O!V\^'8(RAO^\GGP\.(%[_N_DY.##
M82]<P0W4/_B&>(H'#\RX]Q)*E\5#WZX;';S/-I&.HXV@:"J>!!7_:<W=7T4"
M;L+8A%0?XY&Y@WY85)ARAA><(FA=X@(8B"!>"+>YJ131@WHJK$C.SBLS$+A+
MH;#2GQ0R9RY"#?/ [TIW++H%E=RC<4SIH8%._&0<0WTM9@6CJH)7T+[>E7X
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MI9@++(,6=6R%RFWH;&HX;A;HKGF%MN8%/B_7U%A/!49<4_;WYZNOH>>B,P\
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M_@)02P$"% ,4    " !<@-=4M8@%KYP5   WK0  #@              @ $
M    9#<S,#@X.&0X:RYH=&U02P$"% ,4    " !<@-=4I3?9D7E=  #1Q@(
M$               @ '(%0  9#<S,#@X.&1E>#,Q+FAT;5!+ 0(4 Q0    (
M %R UU0)YK2T1 ,  %<+   1              "  6]S  !T979A+3(P,C(P
M-C(S+GAS9%!+ 0(4 Q0    ( %R UU3E9K@&BP8  &E&   5
M  "  >)V  !T979A+3(P,C(P-C(S7VQA8BYX;6Q02P$"% ,4    " !<@-=4
MARL]+\H$   H+   %0              @ &@?0  =&5V82TR,#(R,#8R,U]P
<<F4N>&UL4$L%!@     %  4 /P$  )V"      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
